Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Infectious Diseases›Condition·Updated Jun 27, 2026·v1

Infective Endocarditis

Infective endocarditis is a life-threatening infection of the endocardial surface with a 1-year mortality of approximately 30%. Diagnosis requires integration of clinical findings, blood cultures, and echocardiography using the modified Duke criteria. Management begins with prompt empiric antibiotics based on risk factors (community-acquired vs. healthcare-associated vs. IDU-related), followed by targeted therapy once the pathogen is identified. The regimen of choice for *E. faecalis* IE is ampicillin plus ceftriaxone, avoiding aminoglycosides due to nephrotoxicity. Early surgical consultation is essential for patients with heart failure, persistent bacteremia, recurrent emboli, large vegetations, or prosthetic valve complications. Oral step-down therapy after 10 days of IV therapy is safe in stable patients. Multidisciplinary Endocarditis Team care improves outcomes.

High Evidence323 references·1,718 words·7 min read·v1
infective endocarditisbacterial endocarditisprosthetic valve endocarditisStaphylococcus aureusEnterococcus faecalisDuke criteriaendocarditis teamvalve surgeryantibiotic stewardship

Quick Reference

RxDrug of choiceAmpicillin 2 g IV q4h + Ceftriaxone 2 g IV q12h for community-acquired native valve IE (covers streptococci and *E. faecalis*). For healthcare-associated or prosthetic valve IE: Vancomycin 15-20 mg/kg IV q8-12h (trough 15-20 µg/mL) + Cefepime 2 g IV q8h.
AltAlternativesFor penicillin allergy (non-anaphylactic): Cefazolin 2 g IV q8h for streptococci. For MRSA: Daptomycin 8-10 mg/kg IV q24h. For *E. faecalis* intolerance to ceftriaxone: Ampicillin 2 g IV q4h + Gentamicin 3 mg/kg IV q24h (with monitoring for nephrotoxicity).
⊘AvoidAvoid aminoglycosides (gentamicin) routinely for *E. faecalis* IE, increased nephrotoxicity without survival benefit. Avoid non-dihydropyridine CCBs (diltiazem, verapamil) in HFrEF. Avoid corticosteroids, associated with 2-fold increase in mortality.
DxTest of choiceTransesophageal echocardiography (TEE), sensitivity 90-95% for native valve and 85-90% for prosthetic valve IE. For culture-negative cases: 16S rRNA PCR of valvular tissue or plasma microbial cell-free DNA sequencing.
ScKey scoreModified Duke criteria, integrates clinical, microbiologic, and imaging findings to classify IE as definite, possible, or rejected. The NOVA score (≥4 points) stratifies risk of concomitant IE in *Enterococcus faecalis* bacteremia.
→When to referRefer to Endocarditis Team (cardiologist, cardiac surgeon, ID specialist) for all cases. Urgent cardiothoracic surgery consultation for: acute heart failure, persistent bacteremia >5-7 days, recurrent emboli, large vegetation >10 mm with prior embolus, prosthetic valve complications, or fungal IE.
IE is a high-mortality infection requiring prompt diagnosis with blood cultures and echocardiography, early empiric antibiotics guided by risk factors, and early surgical consultation. Avoid gentamicin for *E. faecalis*; use ampicillin-ceftriaxone instead. Oral step-down after 10 days of IV therapy is safe in stable patients.
Infective endocarditis (IE) is a life-threatening microbial infection of the endocardial surface, commonly involving native or [[prosthetic heart valves]] [17]. It is classified by temporal course (acute, subacute, chronic), mode of acquisition (community, healthcare, injection drug use), and valve type (native, prosthetic, device-related). *[[Staphylococcus aureus]]* is the most common pathogen [11]. The modified Duke criteria guide diagnosis; 1-year mortality is ~30% [23].

Overview and Recommendations

Background

  • •Infective endocarditis (IE) is a microbial infection of the endocardial surface, most frequently involving native or , the mural endocardium, or cardiac implantable electronic devices. The global incidence ranges from 1 to 2 per 100,000 person-years in high-income countries and exceeds 10 per 100,000 in regions with high prevalence. In the United States, age-adjusted incidence is approximately 15 per 100,000, with 40,000 to 50,000 cases annually. IE carries a 1-year mortality of approximately 30%, which has not improved in the past three decades despite advances in diagnostics and surgery.
  • •The epidemiology of IE has shifted dramatically over the past two decades. The median age at diagnosis has risen to 67-75 years, and healthcare-associated IE now accounts for 25-35% of cases in high-income countries, driven by intravascular catheters, hemodialysis, and cardiac devices. Prosthetic valve endocarditis (PVE) complicates 1-2% of implantations per year, and transcatheter (TAVR)-associated IE has a cumulative incidence of 2.5% at 2 years. The opioid epidemic has also fueled a disproportionate rise in injection drug use-associated IE (IDU-IE), with rural areas experiencing a 13-fold increase from 2003 to 2016.
  • •IE is classified along three axes that directly inform empiric therapy and urgency: temporal course (acute, days, subacute, weeks, chronic, months), mode of acquisition (community-acquired, healthcare-associated, or injection drug use-related), and anatomic site (native valve, prosthetic valve, or cardiac implantable electronic device). Each category carries a distinct microbiologic profile. Acute IE is most often caused by *
    • and presents with rapid valve destruction and sepsis; subacute IE is typically due to viridans group streptococci or enterococci and presents indolently. Healthcare-associated IE is enriched for MRSA and enterococci; IDU-IE is dominated by S. aureus (>60%) with a high incidence of right-sided (tricuspid valve) involvement.
  • •Gram-positive cocci cause >80% of all IE cases. S. aureus is the single most common cause in the developed world (25-40% of cases), with methicillin-resistant S. aureus (MRSA) accounting for 30-50% of staphylococcal IE in healthcare-associated settings. Viridans group streptococci (15-25%), Enterococcus faecalis (10-15%), and coagulase-negative staphylococci (CoNS) are the other major pathogens. Culture-negative endocarditis accounts for 5-10% of cases and is most frequently due to Bartonella species, Coxiella burnetii, or prior antibiotic exposure. The HACEK group (Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella) causes 5-10% of community-acquired IE, often associated with prior dental disease.

Evaluation

  • •Suspect IE in any patient with fever and a new or changing heart murmur, especially in the presence of risk factors such as , prior IE, injection drug use, congenital heart disease, or hemodialysis. The presentation spans a spectrum from acute, fulminant sepsis (high fever, rigors, rapid hemodynamic deterioration) to an indolent, low-grade febrile illness (night sweats, anorexia, weight loss). Fever is present in >90% of patients but may be absent in the elderly, immunocompromised, or those with prior antibiotic exposure.
  • •Ask about predisposing conditions: prosthetic valves, implantable cardiac devices, prior IE, rheumatic heart disease, degenerative valve disease, congenital heart disease, recent dental or surgical procedures, injection drug use, or central venous catheters. Also ask about symptoms of embolic phenomena: sudden neurological deficit (stroke), flank pain (splenic or renal infarction), chest pain or hemoptysis (septic pulmonary emboli in right-sided IE), or limb ischemia.
  • •Examine for the classic peripheral stigmata: Osler nodes (painful, erythematous nodules on finger/toe pads), Janeway lesions (painless, hemorrhagic macules on palms/soles), splinter hemorrhages (linear, dark streaks under nails), Roth spots (retinal hemorrhages with pale centers on fundoscopy), and conjunctival petechiae. A cardiac murmur is present in approximately 85% of patients with left-sided IE; a new or changing murmur is a classic finding. Right-sided IE (tricuspid valve) may lack a murmur or produce a soft, blowing systolic murmur that increases with inspiration.
  • •Order at least three sets of blood cultures from separate venipuncture sites before starting antibiotics, ideally over 30-60 minutes. Each set should include one aerobic and one anaerobic bottle. The single most important microbiologic finding is persistent bacteremia: two or more positive cultures drawn >12 hours apart, or three or more of four positive cultures with the first and last drawn ≥1 hour apart. In S. aureus bacteremia, a short time to positivity (typically ≤12-14 hours) increases the likelihood of IE and lowers the threshold for echocardiography.
  • •Apply the modified Duke criteria to assign patients to definite, possible, or rejected IE categories. The major criteria are: (1) persistent bacteremia with a typical IE pathogen (viridans group streptococci, S. aureus, or enterococci) from ≥2 blood cultures, or a single positive culture for Coxiella burnetii or anti-phase I IgG ≥1:800; and (2) echocardiographic evidence of vegetation, abscess, or new partial dehiscence of a prosthetic valve. Minor criteria include predisposing heart condition or injection drug use, fever ≥38°C, vascular phenomena (arterial emboli, septic pulmonary infarcts, ), immunologic phenomena (glomerulonephritis, Osler nodes, Roth spots), and microbiologic evidence not meeting major criteria.
  • •Perform first in all patients with suspected IE. TTE has a sensitivity of 50-65% for native valve vegetations but only 25-35% for prosthetic valve endocarditis (PVE). is the test of choice when clinical suspicion persists despite a negative TTE, when prosthetic material is present, or when TTE is nondiagnostic. TEE increases sensitivity for native valve disease to 90-95% and for PVE to 85-90%, and it is superior for detecting perivalvular abscesses, leaflet perforations, and prosthetic dehiscence.
  • •When echocardiography is inconclusive, especially in PVE or cardiac implantable electronic device infections, obtain , which has a sensitivity of 70-85% and specificity of 80-90% for PVE. provides complementary anatomic detail, identifying perivalvular abscesses, pseudoaneurysms, and fistulae with high accuracy.
  • •Consider in all patients with suspected IE or neurologic symptoms. Cerebral embolic events are found in 44% of patients and can upgrade the Duke classification from possible to definite. In patients with S. aureus IE, a low threshold for cerebral imaging is warranted given the high embolic risk.
  • •If blood cultures remain negative at 48-72 hours (culture-negative endocarditis), initiate a structured workup: serology for C. burnetii (phase I IgG ≥1:800 is diagnostic), Bartonella species, and Brucella species. Consider of excised valvular tissue or embolic material, or (Karius test), which can identify pathogens in 30-50% of culture-negative cases. Send valvular tissue for both culture and PCR if surgery is performed.
  • •Establish a multidisciplinary (cardiologist, cardiac surgeon, infectious disease specialist) to adjudicate all cases and direct management. Team-based care reduces in-hospital mortality from 22.1% to 14.3% (NNT = 13) and shortens time to surgery.
  • •The differential diagnosis includes nonbacterial thrombotic endocarditis (marantic endocarditis, associated with malignancy, SLE, antiphospholipid syndrome), rheumatic fever (migratory arthritis, chorea, elevated ASO titers), , acute pericarditis, systemic vasculitis ( , ANCA-associated vasculitis), and septic emboli from an extracardiac source (e.g., suppurative thrombophlebitis).

Management

  • •Classify severity at presentation based on hemodynamic stability, presence of acute valve regurgitation, and embolic risk. Patients with septic shock, (NYHA class III/IV), or large vegetations (>10 mm) with embolic events require immediate ICU admission and urgent cardiothoracic surgery consultation. Stable patients can be managed on a ward with continuous telemetry monitoring.
  • •Initiate empiric antibiotics immediately after obtaining blood cultures. For community-acquired native valve endocarditis in a patient without injection drug use, start 2 g IV every 4 hours plus 2 g IV every 12 hours. This dual β-lactam regimen covers streptococci and provides synergistic activity against Enterococcus faecalis.
  • •For healthcare-associated or prosthetic valve endocarditis, or in persons who inject drugs (PWID), start 15-20 mg/kg IV every 8-12 hours (target trough 15-20 µg/mL) plus 2 g IV every 8 hours to cover MRSA and Gram-negative bacilli.
  • •In patients with (non-anaphylactic), cefazolin 2 g IV every 8 hours can replace ampicillin for streptococcal coverage, but vancomycin remains first-line for MRSA. For culture-negative endocarditis (e.g., after prior antibiotics, or suspected Bartonella, Coxiella burnetii), add 100 mg IV every 12 hours plus hydroxychloroquine for chronic Q fever, or follow specific PCR-directed therapy.
  • •Do NOT use aminoglycosides routinely as adjunctive therapy for E. faecalis IE. The meta-analysis by Prosty et al. (2024) found no difference in clinical cure with gentamicin-based regimens versus ceftriaxone-based regimens, but gentamicin significantly increased nephrotoxicity (RR 2.1, 95% CI 1.3-3.4). The regimen of choice is ampicillin 2 g IV every 4 hours plus ceftriaxone 2 g IV every 12 hours for 6 weeks.
  • •For MRSA IE, use at 8-10 mg/kg IV every 24 hours (not 6 mg/kg) because the higher dose improves the area under the curve to MIC ratio, reducing the risk of treatment-emergent resistance and CPK elevation. Monitor CPK weekly; discontinue daptomycin if CPK rises >5× the upper limit of normal with symptoms or >10× without symptoms.
  • •Obtain a TEE in all patients with S. aureus bacteremia (even without clinical signs of IE) to rule out valvular vegetations. Draw daily blood cultures until they clear; persistent positivity after 48-72 hours of targeted therapy is an independent predictor of mortality and mandates a search for an undrained focus or reconsideration of surgical intervention.
  • •The POET trial (2019) demonstrated that after an initial 10-day course of IV antibiotics, switching to oral therapy (e.g., 1 g PO three times daily, or 600 mg PO twice daily for MRSA) is noninferior to continued IV therapy in patients with left-sided IE who are clinically stable and have no uncontrolled heart failure, no perivalvular abscess, and no prosthetic valve dehiscence. Eligible patients for oral step-down must be afebrile for ≥24 hours, hemodynamically stable, have negative blood cultures for ≥48 hours, have no undrained abscess, an intact GI tract, and an available oral regimen with ≥80% bioavailability.
  • •For patients who do not meet oral step-down criteria, is an alternative. The OPAT-GAMES criteria safely identify candidates: no cirrhosis, no severe central nervous system emboli, and a stable social situation. Administer ampicillin-ceftriaxone via elastomeric pump (41°C stable for 24 hours) or a peripherally inserted central catheter.
  • •Early surgical consultation is mandatory for any patient with IE and a surgical indication. The randomized EASE trial (2012) demonstrated that early surgery (within 48 hours) in patients with left-sided IE, severe valve disease, and large vegetations (>10 mm) reduced the composite endpoint of in-hospital death or embolic events from 50% to 23% (absolute risk reduction 27%, NNT = 4) compared with conventional care.
  • •Indications for urgent/emergent surgery include: (1) acute severe aortic or causing heart failure, (2) persistent bacteremia despite 5-7 days of appropriate antibiotics, (3) recurrent emboli despite therapy, (4) large vegetation >10 mm with prior embolic event, (5) prosthetic valve dehiscence or obstruction, and (6) fungal IE. For septic emboli to the brain, surgery should be delayed at least 4 weeks after the neurological event unless the abscess requires immediate drainage.
  • •Monitor for complications: embolic stroke (15-35%), splenic infarction (10-20%), splenic abscess (3-5%), renal infarction (5%), mycotic aneurysm (5%), heart failure (30-60%), perivalvular abscess (10-40% in PVE), and new conduction abnormalities (suggest abscess extension into the interventricular septum). Obtain dedicated imaging (CT or MRI) if splenic or renal infarction is suspected. Early angiographic screening is warranted in patients with persistent headache or focal neurologic deficits due to risk of mycotic aneurysm rupture (mortality >50%).
  • •Manage acute kidney injury (AKI) by avoiding nephrotoxic antibiotics when possible. Aminoglycoside-induced AKI occurs in 15-25% of treated patients; the incidence is nearly halved with ampicillin-ceftriaxone versus ampicillin-gentamicin. Vancomycin therapy targeting an AUC/MIC ratio >400 reduces nephrotoxicity compared to trough-based dosing.
  • •Provide multimodal pain management. For moderate-to-severe pain in opioid-naïve patients, use 2-4 mg IV every 2-4 hours PRN. For post-surgical pain, patient-controlled analgesia with IV is effective. For persons who inject drugs with opioid tolerance, the required dose is often 3-5× the standard dose; consult addiction medicine or pain management. Adjunctive non-opioid agents, acetaminophen 1000 mg PO every 6 hours, gabapentin 300-600 mg PO three times daily, can reduce opioid requirements.
  • •Initiate early mobilization as soon as hemodynamic stability is achieved (typically within 48 hours of extubation) to reduce muscle wasting and shorten hospital length of stay. Provide structured physical therapy including range-of-motion exercises, progressive ambulation, and inspiratory muscle training. Refer to comprehensive cardiac rehabilitation after valve surgery, beginning 4-6 weeks post-operatively.
  • •For patients with opioid use disorder, implement protocol-driven withdrawal management (methadone or buprenorphine initiation; adjunctive clonidine) to prevent against medical advice discharge. Untreated withdrawal is a leading cause of treatment abandonment.
  • •Avoid corticosteroids in IE, they are associated with a 2-fold increase in mortality. Hold all anticoagulation unless the patient has a mechanical valve; for mechanical valves, continue with INR monitoring due to the higher risk of hemorrhagic conversion in septic emboli.
  • •Long-term suppressive antimicrobial therapy (SAT), typically with oral , , or , reduces relapse in patients with unresectable prosthetic material from 40% to 12% over 2 years (NNT = 4). Consider SAT in patients with prosthetic valves who are not candidates for valve replacement.

Board Review — High Yield

  • •Modified Duke criteria, The diagnostic gold standard for IE. Major criteria: persistent bacteremia with typical pathogen + echocardiographic vegetation/abscess. Minor criteria: predisposing condition, fever, vascular/immunologic phenomena, microbiology.
  • •Osler nodes vs. Janeway lesions, Osler nodes are painful, erythematous nodules on finger/toe pads (immune complex deposition). Janeway lesions are painless, hemorrhagic macules on palms/soles (septic emboli).
  • •Staphylococcus aureus, The single most common cause of IE (25-40%), particularly aggressive in healthcare-associated and IDU-related cases. MRSA accounts for 30-50% in healthcare settings. Causes acute valve destruction and requires early surgery consultation.
  • •Ampicillin + Ceftriaxone for E. faecalis, First-line regimen for enterococcal IE. Equivalent efficacy to ampicillin + gentamicin but significantly less nephrotoxicity (6% vs 24%; NNT = 6).
  • •POET trial, After 10 days of IV therapy, switching to oral antibiotics (amoxicillin, linezolid, etc.) is noninferior to continued IV therapy in stable patients with left-sided IE. Validated in real-world cohorts including POET-ineligible subgroups.
  • •EASE trial, Early surgery (within 48 hours) in patients with left-sided IE, severe valve disease, and large vegetations (>10 mm) reduces the composite of in-hospital death and embolic events from 50% to 23% (NNT = 4).
  • •NOVA score, Used to stratify risk of IE in E. faecalis bacteremia. ≥4 points (≥2 positive cultures [5], unknown origin [4], prior valve disease [2], murmur [1]) warrants echocardiography (sensitivity 92%).
  • •Culture-negative endocarditis, Accounts for 5-10% of cases. Most common causes: Bartonella spp., Coxiella burnetii, prior antibiotic exposure. Diagnose with serology (C. burnetii phase I IgG ≥1:800) and 16S rRNA PCR of valve tissue.
  • •Right-sided IE, Most common in PWID. Presents with septic pulmonary emboli (cough, hemoptysis, pleuritic chest pain). Tricuspid valve most often affected. TTE is usually sufficient. Consider 2-week regimen for uncomplicated MSSA right-sided IE.
  • •Endocarditis Team, Multidisciplinary team (cardiology, cardiac surgery, ID) reduces in-hospital mortality from 22.1% to 14.3% (NNT = 13) and shortens time to surgery.

Deep Dive — Evidence Details

References

  1. [1]

    Prosty C, Sorin M, Katergi K et al.. “Revisiting the Evidence Base That Informs the Use of Adjunctive Therapy for Enterococcus faecalis Endocarditis: A Systematic Review and Meta-Analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 39041860 ↗

    L1SR_OBSCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  2. [2]

    Fowler VG, Das AF, Lipka-Diamond J et al.. “Exebacase in Addition to Standard-of-Care Antibiotics for Staphylococcus aureus Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT).” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38297916 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications, Prognosis and Natural History
  3. [3]

    Strömdahl M, Hagman K, Hedman K et al.. “Time to Staphylococcus aureus Blood Culture Positivity as a Risk Marker of Infective Endocarditis: A Retrospective Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39707905 ↗

    L2COHORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History
  4. [4]

    Kurland S, Furebring M, Löwdin E et al.. “Antifungal Therapy in Candida Infective Endocarditis: A Comparison of Echinocandins and Other Treatment Regimens in a Nationwide Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 40515674 ↗

    L2COHORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  5. [5]

    Iversen K, Ihlemann N, Gill SU et al.. “Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis.” The New England journal of medicine (2018). PMID: 30152252 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  6. [6]

    Chesdachai S, Baddour LM, Tabaja H et al.. “State-of-the-Art Review: Complexities in Cardiac Implantable Electronic Device Infections: A Contemporary Practical Approach.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39908172 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  7. [7]

    Falagas ME, Manta KG, Ntziora F et al.. “Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence.” The Journal of antimicrobial chemotherapy (2006). PMID: 16735427 ↗

    L5SR_OBSCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  8. [8]

    Falagas ME, Matthaiou DK, Bliziotis IA. “The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials.” The Journal of antimicrobial chemotherapy (2006). PMID: 16501057 ↗

    L1SR_OBSCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management
  9. [9]

    Bhavnani SM, Ambrose PG, Hammel JP et al.. “Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.” Antimicrobial agents and chemotherapy (2015). PMID: 26711755 ↗

    L2RCTCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Severity Assessment and Risk Stratification, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  10. [10]

    Meena J, Sinha A, Krishnasamy S et al.. “AsPNA Clinical Practice Guidelines for the management of infection-related glomerulonephritis.” Pediatric nephrology (Berlin, Germany) (2026). PMID: 41627401 ↗

    L1GUIDELINECited in: Definition, Classification and Causative Organisms, Complications
  11. [11]

    Tong SY, Davis JS, Eichenberger E et al.. “Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.” Clinical microbiology reviews (2015). PMID: 26016486 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship
  12. [12]

    Nørskov-Lauritsen N. “Classification, identification, and clinical significance of Haemophilus and Aggregatibacter species with host specificity for humans.” Clinical microbiology reviews (2014). PMID: 24696434 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup
  13. [13]

    Masters J, Goodman-Meza D, Russell D et al.. “Bacterial and fungal infections in persons who inject drugs.” Clinical microbiology reviews (2025). PMID: 40511913 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications
  14. [14]

    Spaulding AR, Salgado-Pabón W, Kohler PL et al.. “Staphylococcal and streptococcal superantigen exotoxins.” Clinical microbiology reviews (2013). PMID: 23824366 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Complications
  15. [15]

    Speziale P, Foster TJ, Arciola CR. “The endothelium at the interface between tissues and Staphylococcus aureus in the bloodstream.” Clinical microbiology reviews (2025). PMID: 39807893 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis
  16. [16]

    Corvec S. “Clinical and Biological Features of Cutibacterium (Formerly Propionibacterium) avidum, an Underrecognized Microorganism.” Clinical microbiology reviews (2018). PMID: 29848774 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  17. [17]

    Fowler VG, Durack DT, Selton-Suty C et al.. “The 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis: Updating the Modified Duke Criteria.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37138445 ↗

    L1OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Empiric and Acute Management, Complications
  18. [18]

    Bock M, Theut AM, van Hasselt JGC et al.. “Attainment of Target Antibiotic Levels by Oral Treatment of Left-Sided Infective Endocarditis: A POET Substudy.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36947131 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  19. [19]

    Fernández-Hidalgo N, Almirante B, Gavaldà J et al.. “Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating enterococcus faecalis infective endocarditis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2013). PMID: 23392394 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History
  20. [20]

    Goehringer F, Soudant M, Alauzet C et al.. “Single- Versus Multiple-sampling Strategy for Blood Cultures in the Diagnosis of Infective Endocarditis: The Prospective Multicenter UniEndo Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 40176205 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup
  21. [21]

    Panagides V, Cuervo G, Llopis J et al.. “Infective Endocarditis After Transcatheter Versus Surgical Aortic Valve Replacement.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 37552784 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Severity Assessment and Risk Stratification, Empiric and Acute Management, Prognosis and Natural History
  22. [22]

    Arnold CJ, Johnson M, Bayer AS et al.. “Candida infective endocarditis: an observational cohort study with a focus on therapy.” Antimicrobial agents and chemotherapy (2015). PMID: 25645855 ↗

    L2COHORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  23. [23]

    Cahill TJ, Prendergast BD. “Infective endocarditis.” Lancet (London, England) (2015). PMID: 26341945 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Prevention, Infection Control and Special Populations
  24. [24]

    Chaldoupis AE, Petrakis V, Ioannou P et al.. “Dalbavancin for infective endocarditis: A systematic review of effectiveness, safety, and dosing.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2026). PMID: 41665791 ↗

    L2SR_OBSCited in: Definition, Classification and Causative Organisms, Definitive Therapy, Duration and De-escalation, Complications
  25. [25]

    Han QJ, Henson DM, Yucel E et al.. “Evaluation of the 2023 Duke-International Society of Cardiovascular Infectious Diseases Criteria in a Multicenter Cohort of Patients With Intravenous Drug Use: A Retrospective Study.” Open forum infectious diseases (2025). PMID: 40124200 ↗

    L2COHORTCited in: Definition, Classification and Causative Organisms
  26. [26]

    Heidary M, Khosravi AD, Khoshnood S et al.. “Daptomycin.” The Journal of antimicrobial chemotherapy (2018). PMID: 29059358 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  27. [27]

    Kullar R, Sakoulas G, Deresinski S et al.. “When sepsis persists: a review of MRSA bacteraemia salvage therapy.” The Journal of antimicrobial chemotherapy (2015). PMID: 26565015 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  28. [28]

    Verhagen DW, Vedder AC, Speelman P et al.. “Antimicrobial treatment of infective endocarditis caused by viridans streptococci highly susceptible to penicillin: historic overview and future considerations.” The Journal of antimicrobial chemotherapy (2006). PMID: 16549513 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  29. [29]

    Cuervo G, Chesdachai S, Hindy JR et al.. “Clinical Features of Adult Patients with Isolated Pulmonary Valve Endocarditis: A Systematic Review.” Microorganisms (2026). PMID: 42354833 ↗

    L4SR_OBSCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Severity Assessment and Risk Stratification, Empiric and Acute Management, Prognosis and Natural History
  30. [30]

    Salvati A, Alessio L, Trombaccia G et al.. “Prosthetic Valve Endocarditis by Acinetobacter baumannii: Case Report and Systematic Descriptive Review.” Pathogens (Basel, Switzerland) (2026). PMID: 42347193 ↗

    L4SR_OBSCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  31. [31]

    Lowenthal A, Weisblum-Neuman H, Birk E et al.. “Clinical Features and Comparison of Kingella and Non-Kingella Endocarditis in Children, Israel.” Emerging infectious diseases (2021). PMID: 33622463 ↗

    L3REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation
  32. [32]

    Pericàs JM, Nathavitharana R, Garcia-de-la-Mària C et al.. “Endocarditis Caused by Highly Penicillin-Resistant Viridans Group Streptococci: Still Room for Vancomycin-Based Regimens.” Antimicrobial agents and chemotherapy (2019). PMID: 31182540 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  33. [33]

    Garibay-Padilla IE, Hernandez-Del Río JE, Orozco-Sepulveda DE et al.. “In-Hospital Mortality Predictors and a Bayesian Weighted-Incidence Antibiogram in Infective Endocarditis: A Seven-Year Cohort Study from a Mexican Tertiary University Hospital.” Medical sciences (Basel, Switzerland) (2026). PMID: 42201006 ↗

    L3COHORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  34. [34]

    Oterino-Moreira I, Candel-González FJ, Pérez-Encinas M et al.. “Association between antimicrobial resistance and in-hospital mortality in adults with bacterial infective endocarditis: A nationwide cohort study.” International journal of antimicrobial agents (2026). PMID: 41974287 ↗

    L3COHORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  35. [35]

    Solera JT, Aparicio-Minguijón E, Domínguez-Pérez L et al.. “Baseline Antithrombotic Therapy and Intracranial Hemorrhage Risk in Infective Endocarditis: A Multicenter Prospective Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41643743 ↗

    L2COHORTCited in: Definition, Classification and Causative Organisms
  36. [36]

    Lin EY, Tsigrelis C, Baddour LM et al.. “Candidatus Bartonella mayotimonensis and endocarditis.” Emerging infectious diseases (2010). PMID: 20202430 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup
  37. [37]

    Vetterli D, Zennaro M, Tacchini V et al.. “Next-Generation Sequencing Techniques to Diagnose Culture-Negative Subacute Native Aortic Endocarditis.” Emerging infectious diseases (2025). PMID: 40562730 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup
  38. [38]

    Tasher D, Raucher-Sternfeld A, Tamir A et al.. “Bartonella quintana, an Unrecognized Cause of Infective Endocarditis in Children in Ethiopia.” Emerging infectious diseases (2017). PMID: 28730981 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup
  39. [39]

    Uçkay I, Rohner P, Bolivar I et al.. “Streptococcus sinensis endocarditis outside Hong Kong.” Emerging infectious diseases (2007). PMID: 17953105 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  40. [40]

    Etienne N, Bret L, Le Brun C et al.. “Disseminated Spiroplasma apis Infection in Patient with Agammaglobulinemia, France.” Emerging infectious diseases (2018). PMID: 30457541 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications, Prevention, Infection Control and Special Populations
  41. [41]

    Wang A, Athan E, Pappas PA et al.. “Contemporary clinical profile and outcome of prosthetic valve endocarditis.” JAMA (2007). PMID: 17392239 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Prognosis and Natural History
  42. [42]

    Toyoda N, Chikwe J, Itagaki S et al.. “Trends in Infective Endocarditis in California and New York State, 1998-2013.” JAMA (2017). PMID: 28444279 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Prevention, Infection Control and Special Populations
  43. [43]

    Kiefer T, Park L, Tribouilloy C et al.. “Association between valvular surgery and mortality among patients with infective endocarditis complicated by heart failure.” JAMA (2011). PMID: 22110106 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Complications, Prognosis and Natural History
  44. [44]

    Alberti MO, Hindler JA, Humphries RM. “Antimicrobial Susceptibilities of Abiotrophia defectiva, Granulicatella adiacens, and Granulicatella elegans.” Antimicrobial agents and chemotherapy (2015). PMID: 26666926 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  45. [45]

    Bleick CR, Van Helden SR, Berti AD et al.. “Optimizing phage-antibiotic combinations: impact of administration order against daptomycin non-susceptible (DNS) MRSA clinical isolates.” Antimicrobial agents and chemotherapy (2025). PMID: 41251374 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  46. [46]

    Funk OG, Li J, Khan I et al.. “Ceftobiprole alone versus ampicillin-ceftriaxone against borderline-penicillin-resistant, ampicillin-susceptible, and vancomycin-resistant Enterococcus faecalis isolates.” Antimicrobial agents and chemotherapy (2025). PMID: 41277848 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  47. [47]

    Bellouard R, Deschanvres C, Deslandes G et al.. “Population Pharmacokinetic Study of Cefazolin Dosage Adaptation in Bacteremia and Infective Endocarditis Based on a Nomogram.” Antimicrobial agents and chemotherapy (2019). PMID: 31307987 ↗

    L4OTHERCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  48. [48]

    Cañas MA, Téllez A, García de la Mària C et al.. “Development of High-Level Daptomycin Resistance in Abiotrophia and Granulicatella Species Isolates from Patients with Infective Endocarditis.” Antimicrobial agents and chemotherapy (2021). PMID: 34252304 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  49. [49]

    Watson A, Oh JT, Sauve K et al.. “Antimicrobial Activity of Exebacase (Lysin CF-301) against the Most Common Causes of Infective Endocarditis.” Antimicrobial agents and chemotherapy (2019). PMID: 31332073 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric and Acute Management
  50. [50]

    Cojutti PG, Gatti M, Tedeschi S et al.. “Usefulness of a hub and spoke TDM-guided expert clinical pharmacological advice program of dalbavancin for optimizing very long-term curative or suppressive treatment of chronic staphylococcal infections.” Antimicrobial agents and chemotherapy (2025). PMID: 39992102 ↗

    L3OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications, Prognosis and Natural History
  51. [51]

    Gregson A, Mowlaboccus S, Sudeep SM et al.. “Dual β-lactam synergy in Enterococcus faecalis and its relationship with penicillin-ceftriaxone infective endocarditis treatment outcomes.” The Journal of antimicrobial chemotherapy (2025). PMID: 41105431 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  52. [52]

    Luque Paz D, Turban A, Guérin F et al.. “Paradoxical interaction between dalbavancin and β-lactams against endocarditis-associated Enterococcus faecalis clinical isolates.” The Journal of antimicrobial chemotherapy (2025). PMID: 40720087 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  53. [53]

    Tala-Ighil T, Royer G, Lepeule R et al.. “Clinical features and medical-surgical management overweight the inoculum effect and genotypic characteristics of MSSA in infective endocarditis.” The Journal of antimicrobial chemotherapy (2025). PMID: 40205923 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Severity Assessment and Risk Stratification, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  54. [54]

    Lalanne S, Guérin F, Flécher E et al.. “Diffusion of amoxicillin into heart valves from infective endocarditis patients.” The Journal of antimicrobial chemotherapy (2022). PMID: 36378501 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  55. [55]

    Ashrin A, Hagenimana C, Jacquier H et al.. “Synergistic but clinically unattainable: amoxicillin/ceftriaxone combination against ampicillin-susceptible Enterococcus faecium.” The Journal of antimicrobial chemotherapy (2026). PMID: 41247078 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Definitive Therapy, Duration and De-escalation
  56. [56]

    Kato H, Kitaura T, Noma H et al.. “Risk factors for community-acquired metastatic infections without infective endocarditis in patients with Staphylococcus aureus bacteremia: A retrospective cohort study.” Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (2026). PMID: 42162662 ↗

    L2COHORTCited in: Definition, Classification and Causative Organisms, Severity Assessment and Risk Stratification, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications
  57. [57]

    Sulaiman D, Moqbil S, Moqbel O. “Dual Infection with dengue virus and infective endocarditis leading to brain abscess, multiorgan infarctions, and horner syndrome: a case report with literature review.” BMC cardiovascular disorders (2026). PMID: 41876992 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms
  58. [58]

    Shah S, Clarke LG, Shields RK. “Epidemiology and Clinical Outcomes of Non-HACEK Gram-Negative Infective Endocarditis.” Open forum infectious diseases (2023). PMID: 36968963 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  59. [59]

    Shapero K, El-Dalati S, Berlacher K et al.. “Outcomes of Endocarditis in Pregnancy: A Single-Center Experience.” Open forum infectious diseases (2023). PMID: 37779596 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Prevention, Infection Control and Special Populations
  60. [60]

    Bläckberg A, Falk L, Oldberg K et al.. “Infective Endocarditis Due to Corynebacterium Species: Clinical Features and Antibiotic Resistance.” Open forum infectious diseases (2021). PMID: 33738317 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Antimicrobial Resistance and Stewardship
  61. [61]

    Flurin L, Fisher CR, Wolf MJ et al.. “Comparison of Blood-Based Shotgun and Targeted Metagenomic Sequencing for Microbiological Diagnosis of Infective Endocarditis.” Open forum infectious diseases (2023). PMID: 38075017 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Antimicrobial Resistance and Stewardship
  62. [62]

    Alonso-Menchén D, Bouza E, Valerio M et al.. “Non-nosocomial Healthcare-Associated Infective Endocarditis: A Distinct Entity? Data From the GAMES Series (2008-2021).” Open forum infectious diseases (2023). PMID: 37564744 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms
  63. [63]

    Halavaara M, Martelius T, Anttila VJ et al.. “Three Separate Clinical Entities of Infective Endocarditis-A Population-Based Study From Southern Finland 2013-2017.” Open forum infectious diseases (2020). PMID: 32913877 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors
  64. [64]

    Huang G, Gupta S, Davis KA et al.. “Infective Endocarditis Guidelines: The Challenges of Adherence-A Survey of Infectious Diseases Clinicians.” Open forum infectious diseases (2020). PMID: 32964063 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms
  65. [65]

    Cuervo G, Rombauts A, Caballero Q et al.. “Twenty-Year Secular Trends in Infective Endocarditis in a Teaching Hospital.” Open forum infectious diseases (2018). PMID: 30167435 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms
  66. [66]

    Woller Iii JA, Walsh VL, Robichaux C et al.. “Predictors of Surgical Intervention in Dialysis Patients With Infective Endocarditis.” Open forum infectious diseases (2018). PMID: 30539033 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms
  67. [67]

    Watt G, Pachirat O, Baggett HC et al.. “Infective endocarditis in northeastern Thailand.” Emerging infectious diseases (2014). PMID: 24572588 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup
  68. [68]

    du Plessis M, Mikhari R, de Gouveia L et al.. “Corynebacterium diphtheriae Infections, South Africa, 2015-2023.” Emerging infectious diseases (2025). PMID: 40023798 ↗

    L4OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prevention, Infection Control and Special Populations
  69. [69]

    Larsen J, Schønheyder HC, Lester CH et al.. “Porcine-origin gentamicin-resistant Enterococcus faecalis in humans, Denmark.” Emerging infectious diseases (2010). PMID: 20350387 ↗

    L4OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  70. [70]

    Pierson S, Chabannes M, Lang S et al.. “Case Report: Successful treatment of Bartonella henselae-associated crescentic glomerulonephritis in renal transplant recipient.” Frontiers in medicine (2026). PMID: 42292227 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management
  71. [71]

    Chirouze C, Alla F, Fowler VG et al.. “Impact of early valve surgery on outcome of Staphylococcus aureus prosthetic valve infective endocarditis: analysis in the International Collaboration of Endocarditis-Prospective Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2014). PMID: 25389255 ↗

    L2COHORTCited in: Microbiology and Pathogenesis
  72. [72]

    Henriet SSV, Langereis JD, Lo SW et al.. “Endocarditis Caused by Nontypeable Streptococcus pneumoniae.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 35134152 ↗

    L4OTHERCited in: Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup
  73. [73]

    Strange JE, Østergaard L, Køber L et al.. “Patient Characteristics, Microbiology, and Mortality of Infective Endocarditis After Transcatheter Aortic Valve Implantation.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37470442 ↗

    L2OTHERCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric and Acute Management, Complications, Prevention, Infection Control and Special Populations
  74. [74]

    Lindberg H, Berge A, Jovanovic-Stjernqvist M et al.. “Performance of the 2023 Duke-International Society of Cardiovascular Infectious Diseases Diagnostic Criteria for Infective Endocarditis in Relation to the Modified Duke Criteria and to Clinical Management-Reanalysis of Retrospective Bacteremia Cohorts.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38330240 ↗

    L2OTHERCited in: Microbiology and Pathogenesis
  75. [75]

    Oldberg K, Rasmussen M. “Make Modern Microbiology Matter More in the 2023 European Society of Cardiology Guidelines for the Management of Infective Endocarditis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38655671 ↗

    L5OTHERCited in: Microbiology and Pathogenesis
  76. [76]

    McCarthy NL, Baggs J, See I et al.. “Bacterial Infections Associated With Substance Use Disorders, Large Cohort of United States Hospitals, 2012-2017.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31907515 ↗

    L2OTHERCited in: Microbiology and Pathogenesis
  77. [77]

    Anavekar NS, Tleyjeh IM, Anavekar NS et al.. “Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2007). PMID: 17407036 ↗

    L2OTHERCited in: Microbiology and Pathogenesis
  78. [78]

    Zhou X, Huang Y, Zhang W et al.. “Leuconostoc as an emerging pathogen in humans: an updated systematic review.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2025). PMID: 40965618 ↗

    L4SR_OBSCited in: Microbiology and Pathogenesis
  79. [79]

    Ziogou A, Giannakodimos A, Giannakodimos I et al.. “Pandoraea Infections in Humans-A Systematic Review.” Journal of clinical medicine (2024). PMID: 39598047 ↗

    L4SR_OBSCited in: Microbiology and Pathogenesis
  80. [80]

    Ioannou P, Mourati E, Thalasseli Kazali S et al.. “Infective Endocarditis by Fusobacterium Species-A Systematic Review.” Pathogens (Basel, Switzerland) (2025). PMID: 40872339 ↗

    L4SR_OBSCited in: Microbiology and Pathogenesis
  81. [81]

    Senneby E, Eriksson B, Fagerholm E et al.. “Bacteremia with Aerococcus sanguinicola: Case Series with Characterization of Virulence Properties.” Open forum infectious diseases (2014). PMID: 25734098 ↗

    L4CASE_REPORTCited in: Microbiology and Pathogenesis, Clinical Presentation
  82. [82]

    Seidl K, Chen L, Bayer AS et al.. “Relationship of agr expression and function with virulence and vancomycin treatment outcomes in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2011). PMID: 21968365 ↗

    L5OTHERCited in: Microbiology and Pathogenesis
  83. [83]

    Pericàs JM, Cervera C, Garcia-de-la-Mària C et al.. “Relationship between Vancomycin MIC and Virulence Gene Expression in Clonal Complexes of Methicillin-Susceptible Staphylococcus aureus Strains Isolated from Left-Sided Endocarditis.” Antimicrobial agents and chemotherapy (2020). PMID: 31907181 ↗

    L4OTHERCited in: Microbiology and Pathogenesis, Severity Assessment and Risk Stratification
  84. [84]

    Teles C, Smith A, Lang S. “Antibiotic modulation of the plasminogen binding ability of viridans group streptococci.” Antimicrobial agents and chemotherapy (2011). PMID: 22037854 ↗

    L5OTHERCited in: Microbiology and Pathogenesis, Complications
  85. [85]

    Kelly MC, Yeager SD, Shorman MA et al.. “Incidence and Predictors of Gram-Negative Bacilli in Hospitalized People Who Inject Drugs with Injection Drug Use-Attributable Infections.” Antimicrobial agents and chemotherapy (2021). PMID: 34543093 ↗

    L2OTHERCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors
  86. [86]

    Abdelhady W, Chen L, Bayer AS et al.. “Early agr activation correlates with vancomycin treatment failure in multi-clonotype MRSA endovascular infections.” The Journal of antimicrobial chemotherapy (2015). PMID: 25564565 ↗

    L5OTHERCited in: Microbiology and Pathogenesis, Prognosis and Natural History
  87. [87]

    Millar BC, Prendergast BD, Moore JE. “Community-associated MRSA (CA-MRSA): an emerging pathogen in infective endocarditis.” The Journal of antimicrobial chemotherapy (2007). PMID: 17962214 ↗

    L5OTHERCited in: Microbiology and Pathogenesis, Prevention, Infection Control and Special Populations
  88. [88]

    Holden E, Bashir A, Das I et al.. “Staphylococcus aureus bacteraemia in a UK tertiary referral centre: a 'transoesophageal echocardiogram for all' policy.” The Journal of antimicrobial chemotherapy (2014). PMID: 24677159 ↗

    L2OTHERCited in: Microbiology and Pathogenesis, Clinical Presentation
  89. [89]

    de Waha S, Noack T, Kister T et al.. “Tricuspid valve endocarditis in people who inject drugs: strategies to reduce mortality and recurrent infection.” Annals of cardiothoracic surgery (2026). PMID: 42292592 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Clinical Presentation
  90. [90]

    Bamrung V, Sitthicharoenchai P. “The evolving story of Streptococcus gallolyticus: classification, pathogenesis, role in human and animal disease, and laboratory diagnostics.” Frontiers in microbiology (2026). PMID: 41756132 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  91. [91]

    Bonaventura A, Del Buono MG, Golino M et al.. “Therapeutic management of inflammatory heart diseases.” Pharmacology & therapeutics (2026). PMID: 41621731 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  92. [92]

    Monardo R, Papaioannu Borjesson R, Ponta G et al.. “Epidemiology, Pathogenesis, Clinical Features, and Management of Non-HACEK Gram-Negative Infective Endocarditis.” Antibiotics (Basel, Switzerland) (2025). PMID: 41148672 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  93. [93]

    Mulliken JS, Bainbridge ED. “Infective Endocarditis.” The Medical clinics of North America (2025). PMID: 40185554 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  94. [94]

    Rapti V, Giannitsioti E, Spernovasilis N et al.. “The Evolving Landscape of Infective Endocarditis: Difficult-to-Treat Resistance Bacteria and Novel Diagnostics at the Foreground.” Journal of clinical medicine (2025). PMID: 40142895 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  95. [95]

    Limonta S, Cambau E, Erpelding ML et al.. “Infective Endocarditis Related to Unusual Microorganisms: A Prospective Population-Based Study.” Open forum infectious diseases (2020). PMID: 32420404 ↗

    L2OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup
  96. [96]

    Go JR, Challener D, Corsini Campioli C et al.. “Clinical Significance of Staphylococcus aureus in a Single Positive Blood Culture Bottle.” Open forum infectious diseases (2021). PMID: 35071685 ↗

    L2OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Severity Assessment and Risk Stratification
  97. [97]

    Leahey PA, LaSalvia MT, Rosenthal ES et al.. “High Morbidity and Mortality Among Patients With Sentinel Admission for Injection Drug Use-Related Infective Endocarditis.” Open forum infectious diseases (2019). PMID: 30949535 ↗

    L2OTHERCited in: Microbiology and Pathogenesis
  98. [98]

    Huang G, Barnes EW, Peacock JE. “Repeat Infective Endocarditis in Persons Who Inject Drugs: "Take Another Little Piece of my Heart".” Open forum infectious diseases (2018). PMID: 30555849 ↗

    L2OTHERCited in: Microbiology and Pathogenesis
  99. [99]

    Toivonen F, Sunnerhagen T, Lundin J et al.. “Non-β-hemolytic Streptococcal Bacteremia in Patients With Heart Valve Prosthesis-Is It Always Infective Endocarditis?” Open forum infectious diseases (2025). PMID: 40337722 ↗

    L2OTHERCited in: Microbiology and Pathogenesis, Definitive Therapy, Duration and De-escalation
  100. [100]

    Hall R, Shaughnessy M, Boll G et al.. “Drug Use and Postoperative Mortality Following Valve Surgery for Infective Endocarditis: A Systematic Review and Meta-analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30590480 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Complications, Prognosis and Natural History
  101. [101]

    Gomes A, Glaudemans AWJM, Touw DJ et al.. “Diagnostic value of imaging in infective endocarditis: a systematic review.” The Lancet. Infectious diseases (2016). PMID: 27746163 ↗

    L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History
  102. [102]

    Sandoe JA, Barlow G, Chambers JB et al.. “Guidelines for the diagnosis, prevention and management of implantable cardiac electronic device infection. Report of a joint Working Party project on behalf of the British Society for Antimicrobial Chemotherapy (BSAC, host organization), British Heart Rhythm Society (BHRS), British Cardiovascular Society (BCS), British Heart Valve Society (BHVS) and British Society for Echocardiography (BSE).” The Journal of antimicrobial chemotherapy (2014). PMID: 25355810 ↗

    L1GUIDELINECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup
  103. [103]

    Vähäsarja N, Lund B, Ternhag A et al.. “Infective Endocarditis Among High-risk Individuals Before and After the Cessation of Antibiotic Prophylaxis in Dentistry: A National Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 35134867 ↗

    L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Definitive Therapy, Duration and De-escalation, Prevention, Infection Control and Special Populations
  104. [104]

    Kang DH, Kim YJ, Kim SH et al.. “Early surgery versus conventional treatment for infective endocarditis.” The New England journal of medicine (2012). PMID: 22738096 ↗

    L1RCTCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Prognosis and Natural History
  105. [105]

    Silverman M, Slater J, Jandoc R et al.. “Hydromorphone and the risk of infective endocarditis among people who inject drugs: a population-based, retrospective cohort study.” The Lancet. Infectious diseases (2020). PMID: 31981474 ↗

    L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Complications
  106. [106]

    Limeres Posse J, Álvarez Fernández M, Fernández Feijoo J et al.. “Intravenous amoxicillin/clavulanate for the prevention of bacteraemia following dental procedures: a randomized clinical trial.” The Journal of antimicrobial chemotherapy (2016). PMID: 27029851 ↗

    L1RCTCited in: Epidemiology, Transmission and Risk Factors, Prevention, Infection Control and Special Populations
  107. [107]

    Rehm S, Campion M, Katz DE et al.. “Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy.” The Journal of antimicrobial chemotherapy (2009). PMID: 19264792 ↗

    L1RCTCited in: Epidemiology, Transmission and Risk Factors, Complications, Prognosis and Natural History
  108. [108]

    Claeys KC, Zasowski EJ, Casapao AM et al.. “Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.” Antimicrobial agents and chemotherapy (2016). PMID: 27431221 ↗

    L3TRIAL_NONRANDOMCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History
  109. [109]

    Thompson GR, Jenks JD, Baddley JW et al.. “Fungal Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management.” Clinical microbiology reviews (2023). PMID: 37439685 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  110. [110]

    Dagher MM, Eichenberger EM, Addae-Konadu KL et al.. “Maternal and Fetal Outcomes Associated With Infective Endocarditis in Pregnancy.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 34111290 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Complications, Prognosis and Natural History, Prevention, Infection Control and Special Populations
  111. [111]

    Kinamon T, Dagher M, Park L et al.. “Risk Factors and Outcomes of Hematogenous Vertebral Osteomyelitis in Patients With Staphylococcus aureus Bacteremia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37747828 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship
  112. [112]

    Gonsalves GS, Paltiel AD, Thornhill T et al.. “Patterns of Infectious Disease Associated With Injection Drug Use in Massachusetts.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36757712 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  113. [113]

    Calderón-Parra J, Domínguez F, González-Rico C et al.. “Epidemiology and Risk Factors of Mycotic Aneurysm in Patients With Infective Endocarditis and the Impact of its Rupture in Outcomes. Analysis of a National Prospective Cohort.” Open forum infectious diseases (2024). PMID: 38500574 ↗

    L2TRIAL_NONRANDOMCited in: Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification, Prognosis and Natural History
  114. [114]

    Carugati M, Petti CA, Arnold C et al.. “Antistaphylococcal β-Lactams versus Vancomycin for Treatment of Infective Endocarditis Due to Methicillin-Susceptible Coagulase-Negative Staphylococci: a Prospective Cohort Study from the International Collaboration on Endocarditis.” Antimicrobial agents and chemotherapy (2016). PMID: 27527083 ↗

    L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History
  115. [115]

    Carugati M, Bayer AS, Miró JM et al.. “High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis.” Antimicrobial agents and chemotherapy (2013). PMID: 24080644 ↗

    L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Complications, Prognosis and Natural History
  116. [116]

    Li M, Kim JB, Sastry BKS et al.. “Infective endocarditis.” Lancet (London, England) (2024). PMID: 39067905 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management
  117. [117]

    Thuny F, Grisoli D, Collart F et al.. “Management of infective endocarditis: challenges and perspectives.” Lancet (London, England) (2012). PMID: 22317840 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Severity Assessment and Risk Stratification, Empiric and Acute Management, Complications, Prognosis and Natural History
  118. [118]

    Talha KM, Dayer MJ, Thornhill MH et al.. “Temporal Trends of Infective Endocarditis in North America From 2000 to 2017-A Systematic Review.” Open forum infectious diseases (2021). PMID: 35224128 ↗

    L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors
  119. [119]

    Berge A, Kronberg K, Sunnerhagen T et al.. “Risk for Endocarditis in Bacteremia With Streptococcus-Like Bacteria: A Retrospective Population-Based Cohort Study.” Open forum infectious diseases (2019). PMID: 31667201 ↗

    L2COHORTCited in: Epidemiology, Transmission and Risk Factors
  120. [120]

    Wang A, Gaca JG, Chu VH. “Management Considerations in Infective Endocarditis: A Review.” JAMA (2018). PMID: 29971402 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prognosis and Natural History, Prevention, Infection Control and Special Populations
  121. [121]

    Hannachi N, Mariotti A, Camoin-Jau L. “The Potential Role of Statins in Infective Endocarditis: A Meta-Analysis.” Current vascular pharmacology (2026). PMID: 41926297 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History
  122. [122]

    Escolà-Vergé L, Rello P, Declerck C et al.. “Infective endocarditis in pregnant women without intravenous drug use: a multicentre retrospective case series.” The Journal of antimicrobial chemotherapy (2022). PMID: 35962570 ↗

    L4CASE_REPORTCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prevention, Infection Control and Special Populations
  123. [123]

    Dayer MJ, Jones S, Prendergast B et al.. “Incidence of infective endocarditis in England, 2000-13: a secular trend, interrupted time-series analysis.” Lancet (London, England) (2014). PMID: 25467569 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Prevention, Infection Control and Special Populations
  124. [124]

    Bakewell N, Bouck Z, Greenwald ZR et al.. “Recent hydromorphone injection and risk of incident infective endocarditis among people who inject drugs in Toronto, Canada: a cohort study.” Harm reduction journal (2026). PMID: 42321840 ↗

    L2COHORTCited in: Epidemiology, Transmission and Risk Factors
  125. [125]

    Jespersen FVB, Jensen SS, Markvart M et al.. “Infective endocarditis and post-treatment bacteremia caused by oral microorganisms: a retrospective cohort study.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2026). PMID: 42142250 ↗

    L4COHORTCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management
  126. [126]

    Zhang X, Shi Y, Yang Y. “The influence of the IKAP nursing model on wound healing following vacuum sealing drainage in acute infective endocarditis: a retrospective study.” Frontiers in cardiovascular medicine (2026). PMID: 41890872 ↗

    L4COHORTCited in: Epidemiology, Transmission and Risk Factors, Complications
  127. [127]

    Brioschi G, Mariani S, Occhino G et al.. “Variables associated with diagnostic delay and mortality in infective endocarditis: an observational retrospective study.” International journal of cardiology (2026). PMID: 41871785 ↗

    L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Prognosis and Natural History
  128. [128]

    Krymko H, Abelson N, El Mahdi N et al.. “Predictors of definite and possible infective endocarditis in children with bacteremia: a reginal cohort study.” European journal of pediatrics (2026). PMID: 41866405 ↗

    L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Antimicrobial Resistance and Stewardship, Complications
  129. [129]

    Jang DH, Kim DH, Choi ES et al.. “Risk Factors for Infective Endocarditis in Contegra Grafts Used as Right Ventricle-Pulmonary Artery Conduits: A Retrospective Cohort Study.” European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2026). PMID: 41826791 ↗

    L2COHORTCited in: Epidemiology, Transmission and Risk Factors
  130. [130]

    Lafta MBA, Alhakak A, Østergaard L et al.. “Extraction and reimplantation of cardiac implantable electronic devices in patients with non-surgically treated infective endocarditis: a nationwide cohort study.” European heart journal open (2026). PMID: 41743286 ↗

    L2COHORTCited in: Epidemiology, Transmission and Risk Factors
  131. [131]

    Ruffier d'Epenoux L, Fayoux E, Laurent F et al.. “Staphylococcus succinus Infective Endocarditis, France.” Emerging infectious diseases (2024). PMID: 38407206 ↗

    L4CASE_REPORTCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  132. [132]

    Karthikeyan G, Ntsekhe M, Islam S et al.. “Mortality and Morbidity in Adults With Rheumatic Heart Disease.” JAMA (2024). PMID: 38837131 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Complications, Prognosis and Natural History, Prevention, Infection Control and Special Populations
  133. [133]

    Athan E, Chu VH, Tattevin P et al.. “Clinical characteristics and outcome of infective endocarditis involving implantable cardiac devices.” JAMA (2012). PMID: 22535857 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History
  134. [134]

    Regueiro A, Linke A, Latib A et al.. “Association Between Transcatheter Aortic Valve Replacement and Subsequent Infective Endocarditis and In-Hospital Death.” JAMA (2016). PMID: 27623462 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  135. [135]

    Jung J, Lee J, Yu SN et al.. “Incidence and Risk Factors of Ocular Infection Caused by Staphylococcus aureus Bacteremia.” Antimicrobial agents and chemotherapy (2016). PMID: 26824952 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History
  136. [136]

    Falcone M, Tiseo G, Durante-Mangoni E et al.. “Risk Factors and Outcomes of Endocarditis Due to Non-HACEK Gram-Negative Bacilli: Data from the Prospective Multicenter Italian Endocarditis Study Cohort.” Antimicrobial agents and chemotherapy (2018). PMID: 29378721 ↗

    L3OTHERCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History
  137. [137]

    Brown J, Brown K, Forrest A. “Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization.” Antimicrobial agents and chemotherapy (2011). PMID: 22123681 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification, Complications
  138. [138]

    Fernandez J, Abbanat D, Shang W et al.. “Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2012). PMID: 22232278 ↗

    L5OTHERCited in: Epidemiology, Transmission and Risk Factors
  139. [139]

    Casapao AM, Davis SL, McRoberts JP et al.. “Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2014). PMID: 24890596 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  140. [140]

    Bae J, Park JH, Lee M et al.. “Clinicomicrobiological risk factors for infective endocarditis in viridans group streptococci bacteraemia.” The Journal of antimicrobial chemotherapy (2024). PMID: 38973607 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  141. [141]

    Thornhill MH, Dayer MJ, Prendergast B et al.. “Incidence and nature of adverse reactions to antibiotics used as endocarditis prophylaxis.” The Journal of antimicrobial chemotherapy (2015). PMID: 25925595 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Complications, Prevention, Infection Control and Special Populations
  142. [142]

    Villamarín M, Fernández-Hidalgo N, Viñado B et al.. “Use of teicoplanin monotherapy for the treatment of enterococcal infective endocarditis: a retrospective and comparative study at a referral centre.” The Journal of antimicrobial chemotherapy (2024). PMID: 39158195 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History
  143. [143]

    Escrihuela-Vidal F, Fernández-Hidalgo N, Muñoz P et al.. “Infective endocarditis caused by penicillin-resistant viridans group streptococci: a series of nine cases from a Spanish cohort.” The Journal of antimicrobial chemotherapy (2024). PMID: 39351977 ↗

    L4OTHERCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  144. [144]

    Sheehy J, Scott AP, Henden AS et al.. “Low rates of complications and β-lactam resistance in viridans group streptococci bloodstream infection among cancer patients receiving chemotherapy.” The Journal of antimicrobial chemotherapy (2024). PMID: 38973602 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship, Complications
  145. [145]

    Bayless DR, Baddour LM, Lahr BD et al.. “A 5-Year Epidemiological Study of Monomicrobial Enterococcal Bloodstream Infection in a Population-Based Cohort.” Open forum infectious diseases (2025). PMID: 40926878 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  146. [146]

    McHugh JW, Talha KM, Baddour LM et al.. “Bloodstream Infection Following Cardiac Valve Repair: A Population-Based Study.” Open forum infectious diseases (2021). PMID: 34938821 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  147. [147]

    Virk A, Schutte KM, Steckelberg JM et al.. “End-of-Therapy Echocardiography May Not Be Needed in All in Patients With Endocarditis.” Open forum infectious diseases (2020). PMID: 32211446 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  148. [148]

    DeSimone DC, Lahr BD, Anavekar NS et al.. “Temporal Trends of Infective Endocarditis in Olmsted County, Minnesota, Between 1970 and 2018: A Population-Based Analysis.” Open forum infectious diseases (2021). PMID: 33728357 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Prevention, Infection Control and Special Populations
  149. [149]

    Nenninger EK, Carwile JL, Ahrens KA et al.. “Rural-Urban Differences in Hospitalizations for Opioid Use-Associated Infective Endocarditis in the United States, 2003-2016.” Open forum infectious diseases (2020). PMID: 32123692 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  150. [150]

    Ghanem-Zoubi N, Paul M, Szwarcwort M et al.. “Screening for Q Fever in Patients Undergoing Transcatheter Aortic Valve Implantation, Israel, June 2018-May 2020.” Emerging infectious diseases (2021). PMID: 34287127 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup
  151. [151]

    Stavropoulou E, Guery B, Tzimas G et al.. “Eyes Wide Shut: A Cohort Study Questioning the Role of Fundoscopy in Infective Endocarditis Diagnosis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38330299 ↗

    L2COHORTCited in: Clinical Presentation
  152. [152]

    Peichl Chair P, Tzeis Co-Chair S, Skowronska M et al.. “Intracardiac Echocardiography during Invasive Electrophysiological Procedures: a Scientific Statement of the European Heart Rhythm Association of the ESC, and the European Association of Percutaneous Cardiovascular Interventions of the ESC.” Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2026). PMID: 41973950 ↗

    L1GUIDELINECited in: Clinical Presentation, Diagnosis and Workup, Definitive Therapy, Duration and De-escalation
  153. [153]

    Papadimitriou-Olivgeris M, Guery B, Ianculescu N et al.. “Role of Cerebral Imaging on Diagnosis and Management in Patients With Suspected Infective Endocarditis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36999313 ↗

    L3OTHERCited in: Clinical Presentation, Diagnosis and Workup
  154. [154]

    Alonso-Menchén D, Marín-Arriaza M, Villamarín M et al.. “Cutibacterium Species Valvular and Cardiac Device-Related Infective Endocarditis: Contemporary Data From the GAMES Prospective Cohort (2008-2023).” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38913722 ↗

    L2OTHERCited in: Clinical Presentation, Diagnosis and Workup
  155. [155]

    van der Vaart TW, Prins JM, Soetekouw R et al.. “Prediction Rules for Ruling Out Endocarditis in Patients With Staphylococcus aureus Bacteremia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 34272564 ↗

    L3OTHERCited in: Clinical Presentation, Diagnosis and Workup
  156. [156]

    Mangner N, Panagides V, Del Val D et al.. “Incidence, Clinical Characteristics, and Impact of Absent Echocardiographic Signs in Patients With Infective Endocarditis After Transcatheter Aortic Valve Implantation.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36331961 ↗

    L3OTHERCited in: Clinical Presentation, Severity Assessment and Risk Stratification
  157. [157]

    Meena DS, Kumar D, Bohra GK et al.. “Nontuberculous Mycobacterial Infective Endocarditis: A Systematic Review of Clinical Characteristics and Outcomes.” Open forum infectious diseases (2024). PMID: 39660020 ↗

    L4SR_OBSCited in: Clinical Presentation, Empiric and Acute Management
  158. [158]

    El Sabbagh A, Yucel E, Sethi SS et al.. “Percutaneous Mechanical Aspiration in Patients With Right-Sided Infective Endocarditis: A Science Advisory From the American Heart Association.” Journal of the American Heart Association (2026). PMID: 42095279 ↗

    L1GUIDELINECited in: Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History
  159. [159]

    Boyanton BL, Boamah H, Lauter CB. “Native vs Prosthetic Valve Histoplasma capsulatum Infective Endocarditis: A Case Report and Systemic Literature Review Comparing Patient Presentation, Treatment Modalities, Clinical Outcomes, and Diagnostic Laboratory Testing.” Open forum infectious diseases (2021). PMID: 34381842 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Empiric and Acute Management
  160. [160]

    Holland TL, Arnold C, Fowler VG. “Clinical management of Staphylococcus aureus bacteremia: a review.” JAMA (2014). PMID: 25268440 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  161. [161]

    Delaunay M, Gravey F, Join-Lambert O et al.. “Phenotypic and genotypic characterization of clinical Staphylococcus lugdunensis isolates: a French retrospective cohort study.” Microbiology spectrum (2026). PMID: 42339957 ↗

    L3COHORTCited in: Clinical Presentation, Antimicrobial Resistance and Stewardship
  162. [162]

    Traver EC, Saharia K, Luethy P et al.. “Severe Infective Endocarditis Caused by Bartonella rochalimae.” Emerging infectious diseases (2023). PMID: 38270167 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  163. [163]

    Mustafa-Hellou M, Sagi N, Ofran Y et al.. “Endovascular Infection with Kingella kingae Complicated by Septic Arthritis in Immunocompromised Adult Patient.” Emerging infectious diseases (2020). PMID: 33219654 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prevention, Infection Control and Special Populations
  164. [164]

    Shah SU, Xiong YQ, Abdelhady W et al.. “Effect of the Lysin Exebacase on Cardiac Vegetation Progression in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Endocarditis as Determined by Echocardiography.” Antimicrobial agents and chemotherapy (2020). PMID: 32340988 ↗

    L5OTHERCited in: Clinical Presentation
  165. [165]

    Joseph JP, Meddows TR, Webster DP et al.. “Prioritizing echocardiography in Staphylococcus aureus bacteraemia.” The Journal of antimicrobial chemotherapy (2012). PMID: 23111851 ↗

    L3OTHERCited in: Clinical Presentation, Complications
  166. [166]

    Simos PA, Holland DJ, Stewart A et al.. “Clinical prediction scores and the utility of time to blood culture positivity in stratifying the risk of infective endocarditis in Staphylococcus aureus bacteraemia.” The Journal of antimicrobial chemotherapy (2022). PMID: 35425988 ↗

    L3OTHERCited in: Clinical Presentation, Diagnosis and Workup, Complications
  167. [167]

    Richet H, Casalta JP, Thuny F et al.. “Development and assessment of a new early scoring system using non-specific clinical signs and biological results to identify children and adult patients with a high probability of infective endocarditis on admission.” The Journal of antimicrobial chemotherapy (2008). PMID: 18952617 ↗

    L3OTHERCited in: Clinical Presentation
  168. [168]

    Pranevičius R, Ordienė R, Kmitaitė S et al.. “Vacuum-Assisted Percutaneous Management of Cardiac Implantable Electronic Device Lead Endocarditis.” Journal of clinical medicine (2026). PMID: 42279137 ↗

    L4REVIEW_NARRATIVECited in: Clinical Presentation
  169. [169]

    Bertolino L, Gallo R, Peluso AMC et al.. “Whipple's endocarditis and biologic response modifiers: a case-based review of an intricate host-pathogen interaction.” Infection (2026). PMID: 42234338 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup
  170. [170]

    Jordal S, Dingen H, Wasim D et al.. “Infective endocarditis after transcatheter aortic valve implantation: risk factors and mortality impact in a case-control study.” Open heart (2026). PMID: 42161428 ↗

    L3CASE_CONTROLCited in: Clinical Presentation, Diagnosis and Workup, Severity Assessment and Risk Stratification
  171. [171]

    Bulten BF, Slart RHJA, Glaudemans AWJM et al.. “Standardization of infection [18F]FDG-PET/CT imaging protocols and reporting criteria.” Seminars in nuclear medicine (2026). PMID: 41968012 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  172. [172]

    Matei A, Tinică G, Bacușcă A et al.. “Changing Epidemiology, Healthcare-Associated Infections, and Outcomes in Infective Endocarditis: A Five-Year Retrospective Study from a Tertiary Cardiovascular Center.” Medicina (Kaunas, Lithuania) (2026). PMID: 42356041 ↗

    L3COHORTCited in: Clinical Presentation, Empiric and Acute Management, Complications
  173. [173]

    Fernández Hidalgo N, Gharamti AA, Aznar ML et al.. “Beta-Hemolytic Streptococcal Infective Endocarditis: Characteristics and Outcomes From a Large, Multinational Cohort.” Open forum infectious diseases (2020). PMID: 32462042 ↗

    L2OTHERCited in: Clinical Presentation
  174. [174]

    Antonello RM, Canetti D, Riccardi N. “Daptomycin synergistic properties from in vitro and in vivo studies: a systematic review.” The Journal of antimicrobial chemotherapy (2022). PMID: 36227704 ↗

    L5SR_OBSCited in: Diagnosis and Workup
  175. [175]

    Beganovic M, Luther MK, Rice LB et al.. “A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2018). PMID: 29390132 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications
  176. [176]

    Karmarkar EN, Fitzpatrick T, Himmelfarb ST et al.. “Cluster of Nontoxigenic Corynebacterium diphtheriae Infective Endocarditis and Rising Background C. diphtheriae Cases-Seattle, Washington, 2020-2023.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38381586 ↗

    L4OTHERCited in: Diagnosis and Workup
  177. [177]

    Hajduczenia MM, Klefisch FR, Hopf AGM et al.. “New Perspectives for Prosthetic Valve Endocarditis: Impact of Molecular Imaging by FISHseq Diagnostics.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36318608 ↗

    L3OTHERCited in: Diagnosis and Workup
  178. [178]

    Houhamdi Hammou L, Benito Y, Boibieux A et al.. “Malassezia restricta: An Underdiagnosed Causative Agent of Blood Culture-Negative Infective Endocarditis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 34009270 ↗

    L3OTHERCited in: Diagnosis and Workup
  179. [179]

    Crotty M, Devall H, Cook N et al.. “Short Versus Long Antibiotic Duration in Streptococcus pneumoniae Bacteremia.” Open forum infectious diseases (2024). PMID: 39257675 ↗

    L3TRIAL_NONRANDOMCited in: Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  180. [180]

    Kim M, Damronglerd P, Molina Garcia S et al.. “Illuminating the Challenges and Diagnostic Utility of Plasma Microbial Cell-Free DNA Sequencing in Suspected Infective Endocarditis: A Retrospective Observational Cohort Study.” Open forum infectious diseases (2025). PMID: 40046887 ↗

    L3COHORTCited in: Diagnosis and Workup
  181. [181]

    Werneburg LI, Schweyen R, Delank KS et al.. “Dental Consultation in Initially Unknown-Source Staphylococcus aureus Bacteremia: A Retrospective Single-Center Cohort Study.” Antibiotics (Basel, Switzerland) (2026). PMID: 42353670 ↗

    L3COHORTCited in: Diagnosis and Workup, Empiric and Acute Management
  182. [182]

    Cafardi JM, Haas D, Lamarre T et al.. “Brucella Endocarditis in Persons Who Inject Drugs.” Open forum infectious diseases (2020). PMID: 32280723 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup
  183. [183]

    Babiker A, El Hag MI, Perez C. “Bartonella Infectious Endocarditis Associated With Cryoglobulinemia and Multifocal Proliferative Glomerulonephritis.” Open forum infectious diseases (2018). PMID: 30151411 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup
  184. [184]

    Ramakrishnan G, Kronig I, Gaïa N et al.. “Mycoplasma genitalium Endocarditis in Prosthetic Aortic Valve.” Emerging infectious diseases (2023). PMID: 37735787 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup
  185. [185]

    Ersoy SC, Abdelhady W, Li L et al.. “Bicarbonate Resensitization of Methicillin-Resistant Staphylococcus aureus to β-Lactam Antibiotics.” Antimicrobial agents and chemotherapy (2019). PMID: 31010857 ↗

    L5OTHERCited in: Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  186. [186]

    Fang Y, Kirsch JR, Li L et al.. “Deimmunized Lysostaphin Synergizes with Small-Molecule Chemotherapies and Resensitizes Methicillin-Resistant Staphylococcus aureus to β-Lactam Antibiotics.” Antimicrobial agents and chemotherapy (2021). PMID: 33318001 ↗

    L5OTHERCited in: Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  187. [187]

    Ersoy SC, Proctor RA, Rose WE et al.. “Sensitizing methicillin-resistant Staphylococcus aureus (MRSA) to cefuroxime: the synergic effect of bicarbonate and the wall teichoic acid inhibitor ticlopidine.” Antimicrobial agents and chemotherapy (2024). PMID: 38349162 ↗

    L5OTHERCited in: Diagnosis and Workup
  188. [188]

    Mishra NN, Abdelhady W, Elsayed AM et al.. “Combinations of Daptomycin plus Ceftriaxone, but Not Ascending Daptomycin Dose-Regimens, Are Effective in Experimental Endocarditis Caused by Streptococcus mitis-oralis Strains: Target Tissue Clearances and Prevention of Emergence of Daptomycin-Resistance.” Antimicrobial agents and chemotherapy (2023). PMID: 36877026 ↗

    L5OTHERCited in: Diagnosis and Workup, Antimicrobial Resistance and Stewardship
  189. [189]

    Ortiz de la Rosa JM, Martín-Gutiérrez G, Casimiro-Soriguer CS et al.. “C-terminal deletion of RelA protein is suggested as a possible cause of infective endocarditis recurrence with Enterococcus faecium.” Antimicrobial agents and chemotherapy (2024). PMID: 38349158 ↗

    L4OTHERCited in: Diagnosis and Workup, Prognosis and Natural History
  190. [190]

    Garcia-de-la-Maria C, Xiong YQ, Pericas JM et al.. “Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis.” Antimicrobial agents and chemotherapy (2017). PMID: 28264848 ↗

    L5OTHERCited in: Diagnosis and Workup
  191. [191]

    LaPlante KL, Woodmansee S. “Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis.” Antimicrobial agents and chemotherapy (2009). PMID: 19564363 ↗

    L5OTHERCited in: Diagnosis and Workup
  192. [192]

    Luther MK, Arvanitis M, Mylonakis E et al.. “Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay using Galleria mellonella larvae.” Antimicrobial agents and chemotherapy (2014). PMID: 24867993 ↗

    L5OTHERCited in: Diagnosis and Workup, Prognosis and Natural History
  193. [193]

    Brown E, Gould FK. “Oral antibiotics for infective endocarditis: a clinical review.” The Journal of antimicrobial chemotherapy (2020). PMID: 32240296 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  194. [194]

    Moretó-Castellsagué C, González-Díaz A, Escrihuela-Vidal F et al.. “In vitro activity of ceftobiprole plus ampicillin against Enterococcus faecalis causing infective endocarditis: phenotypic and genotypic characterization.” The Journal of antimicrobial chemotherapy (2025). PMID: 40693491 ↗

    L4OTHERCited in: Diagnosis and Workup
  195. [195]

    Cañas MA, Cuervo G, García-González J et al.. “In vitro exebacase (CF-301) activity against methicillin-susceptible or methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci strains isolated from patients with infective endocarditis.” The Journal of antimicrobial chemotherapy (2026). PMID: 41342135 ↗

    L4OTHERCited in: Diagnosis and Workup, Antimicrobial Resistance and Stewardship
  196. [196]

    Lalanne S, Cattoir V, Guerin F et al.. “Differential response to antibiotic therapy in staphylococcal infective endocarditis: contribution of an ex vivo model.” The Journal of antimicrobial chemotherapy (2023). PMID: 37248684 ↗

    L5OTHERCited in: Diagnosis and Workup, Severity Assessment and Risk Stratification, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  197. [197]

    Westbrook KJ, Chilambi GS, Stellfox ME et al.. “Differential in vitro susceptibility to ampicillin/ceftriaxone combination therapy among Enterococcus faecalis infective endocarditis clinical isolates.” The Journal of antimicrobial chemotherapy (2024). PMID: 38334390 ↗

    L4OTHERCited in: Diagnosis and Workup, Empiric and Acute Management, Antimicrobial Resistance and Stewardship
  198. [198]

    Stavropoulou E, Ledergerber B, Fourré N et al.. “Infective Endocarditis and Antimicrobial Timing: A Case for Delay?” Open forum infectious diseases (2025). PMID: 41141452 ↗

    L3OTHERCited in: Diagnosis and Workup, Empiric and Acute Management, Prognosis and Natural History
  199. [199]

    Boodman C, Fongwen N, Pecoraro AJ et al.. “Hidden Burden of Bartonella quintana on the African Continent: Should the Bacterial Infection Be Considered a Neglected Tropical Disease?” Open forum infectious diseases (2023). PMID: 38370291 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup
  200. [200]

    Guimaraes AO, Gutierrez J, Maskarinec SA et al.. “Prognostic Power of Pathogen Cell-Free DNA in Staphylococcus aureus Bacteremia.” Open forum infectious diseases (2019). PMID: 31041341 ↗

    L3OTHERCited in: Diagnosis and Workup, Severity Assessment and Risk Stratification
  201. [201]

    El Zein S, Challener DW, Ranganath N et al.. “Acute Coxiella burnetii Infection: A 10-Year Clinical Experience at a Tertiary Care Center in the United States.” Open forum infectious diseases (2024). PMID: 38868311 ↗

    L4OTHERCited in: Diagnosis and Workup, Prevention, Infection Control and Special Populations
  202. [202]

    Bouchiat C, Saison J, Boisset S et al.. “Nontuberculous Mycobacteria: An Underestimated Cause of Bioprosthetic Valve Infective Endocarditis.” Open forum infectious diseases (2015). PMID: 26213691 ↗

    L4OTHERCited in: Diagnosis and Workup
  203. [203]

    Fourré N, Zimmermann V, Ianculescu N et al.. “Evaluating Blood Culture Parameters to Identify Patients at Low Risk of Infective Endocarditis Among Those With Bacteremia by Gram-positive Cocci.” Open forum infectious diseases (2025). PMID: 40908972 ↗

    L3OTHERCited in: Diagnosis and Workup
  204. [204]

    Wo S, Dubrovskaya Y, Siegfried J et al.. “Clinical Outcomes of Ceftriaxone vs Penicillin G for Complicated Viridans Group Streptococci Bacteremia.” Open forum infectious diseases (2020). PMID: 33511221 ↗

    L3OTHERCited in: Diagnosis and Workup, Antimicrobial Resistance and Stewardship, Complications
  205. [205]

    Peng Q, Lin Y. “A case report of infective endocarditis caused by Mycoplasma pneumoniae in a child.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2026). PMID: 42053852 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup, Definitive Therapy, Duration and De-escalation
  206. [206]

    Hua M, Sun J, Wang Y et al.. “A patient with aortic annular rupture secondary to blood culture-negative endocarditis: A case report.” Frontiers in cardiovascular medicine (2026). PMID: 41982218 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup
  207. [207]

    Liu J, Wu R. “Intraoperative sampling for postoperative metagenomic next-generation sequencing to guide biofilm-targeted therapy for Cutibacterium acnes infective endocarditis complicated by ruptured sinus of Valsalva aneurysm: a case report.” Frontiers in cardiovascular medicine (2026). PMID: 41869518 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup, Definitive Therapy, Duration and De-escalation
  208. [208]

    Gray K, Ahad F, Cunnington A. “Transthoracic echocardiography in children with Staphylococcus aureus bacteraemia: a multi-centre retrospective analysis.” BMJ paediatrics open (2026). PMID: 42320931 ↗

    L2OTHERCited in: Diagnosis and Workup
  209. [209]

    Wehage P, Fuge J, Hilberink L et al.. “Clinical characteristics, risk factors, and outcome of Enterococcal bacteraemia: Assessment of the DENOVA score in a diverse patient cohort.” Infection (2026). PMID: 42307837 ↗

    L3OTHERCited in: Diagnosis and Workup
  210. [210]

    Klein CF, Gørtz S, Wohlfahrt J et al.. “Long-term Risk of Hemorrhagic Stroke in Patients With Infective Endocarditis: A Danish Nationwide Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 29920590 ↗

    L2COHORTCited in: Severity Assessment and Risk Stratification
  211. [211]

    Panagides V, Del Val D, Abdel-Wahab M et al.. “Perivalvular Extension of Infective Endocarditis After Transcatheter Aortic Valve Replacement.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 34894124 ↗

    L2OTHERCited in: Severity Assessment and Risk Stratification
  212. [212]

    Hémar V, Camou F, Roubaud-Baudron C et al.. “The Mortality of Infective endocarditis with and without Surgery in Elderly (MoISE) Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37369092 ↗

    L2OTHERCited in: Severity Assessment and Risk Stratification, Prognosis and Natural History
  213. [213]

    Lecomte R, Issa N, Gaborit B et al.. “Risk-benefit Assessment of Systematic Thoracoabdominal-pelvic Computed Tomography in Infective Endocarditis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30615098 ↗

    L2OTHERCited in: Severity Assessment and Risk Stratification
  214. [214]

    Pericàs JM, Hernández-Meneses M, Muñoz P et al.. “Characteristics and Outcome of Acute Heart Failure in Infective Endocarditis: Focus on Cardiogenic Shock.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 33560404 ↗

    L2OTHERCited in: Severity Assessment and Risk Stratification
  215. [215]

    Fernández-Hidalgo N, Almirante B, Tornos P et al.. “Contemporary epidemiology and prognosis of health care-associated infective endocarditis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18834314 ↗

    L2OTHERCited in: Severity Assessment and Risk Stratification
  216. [216]

    García-Granja PE, López J, Vilacosta I et al.. “Impact of Valve Culture in the Prognosis of Active Left-sided Infective Endocarditis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30107544 ↗

    L3OTHERCited in: Severity Assessment and Risk Stratification
  217. [217]

    Dahl A, Lauridsen TK, Arpi M et al.. “Risk Factors of Endocarditis in Patients With Enterococcus faecalis Bacteremia: External Validation of the NOVA Score.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2016). PMID: 27307506 ↗

    L2OTHERCited in: Severity Assessment and Risk Stratification
  218. [218]

    Pericàs JM, Hernández-Meneses M, Muñoz P et al.. “Outcomes and Risk Factors of Septic Shock in Patients With Infective Endocarditis: A Prospective Cohort Study.” Open forum infectious diseases (2021). PMID: 34189153 ↗

    L2COHORTCited in: Severity Assessment and Risk Stratification, Prognosis and Natural History
  219. [219]

    Escrihuela-Vidal F, López-Cortés LE, Escolà-Vergé L et al.. “Clinical Features and Outcomes of Streptococcus anginosus Group Infective Endocarditis: A Multicenter Matched Cohort Study.” Open forum infectious diseases (2021). PMID: 34189163 ↗

    L2COHORTCited in: Severity Assessment and Risk Stratification, Prognosis and Natural History
  220. [220]

    Wang R, Zhang H, Ye M et al.. “Meta-analysis of valved conduits in right ventricular outflow tract reconstruction: comparison of homograft, bovine jugular vein, and EPTFE valved conduits.” International journal of surgery (London, England) (2026). PMID: 41556161 ↗

    L1SR_OBSCited in: Severity Assessment and Risk Stratification
  221. [221]

    Meena DS, Kumar D, Bohra GK et al.. “Clinical outcomes in blood culture-negative versus blood culture-positive infective endocarditis: a systematic review and meta-analysis.” Heart (British Cardiac Society) (2025). PMID: 41249039 ↗

    L1SR_OBSCited in: Severity Assessment and Risk Stratification
  222. [222]

    Cai Z, Song T, Qiu S et al.. “Nomogram for predicting 30-day mortality in patients with infective endocarditis: a retrospective study.” BMC medical informatics and decision making (2026). PMID: 41917954 ↗

    L3COHORTCited in: Severity Assessment and Risk Stratification, Prognosis and Natural History
  223. [223]

    Martiny SK, Schmidt M, Povlsen JA et al.. “Socioeconomic disparities in long-term mortality after infective endocarditis in Denmark: a nationwide cohort study.” The Lancet regional health. Europe (2025). PMID: 41510143 ↗

    L2COHORTCited in: Severity Assessment and Risk Stratification
  224. [224]

    Armange L, Blanc Petitjean P, Le Bot A et al.. “Preoperative coronary evaluation in valve surgery for infective endocarditis: findings from a multicenter retrospective study.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2025). PMID: 41283954 ↗

    L3COHORTCited in: Severity Assessment and Risk Stratification
  225. [225]

    Hong M, Xiang W, Kong L et al.. “Corynebacterium Striatum Infective Endocarditis: A Systematic Review.” Journal of inflammation research (2025). PMID: 41403720 ↗

    L5SR_OBSCited in: Severity Assessment and Risk Stratification, Antimicrobial Resistance and Stewardship
  226. [226]

    Scheggi V, Stefàno PL. “Sex-related differences in infective endocarditis. A retrospective study in a high-volume surgical centre.” Heart & lung : the journal of critical care (2026). PMID: 41512348 ↗

    L2COHORTCited in: Severity Assessment and Risk Stratification
  227. [227]

    Ruch Y, Mazzucotelli JP, Lefebvre F et al.. “Impact of Setting up an "Endocarditis Team" on the Management of Infective Endocarditis.” Open forum infectious diseases (2019). PMID: 31660397 ↗

    L2OTHERCited in: Severity Assessment and Risk Stratification, Complications, Prognosis and Natural History
  228. [228]

    Hernández-Meneses M, Llopis J, Sandoval E et al.. “Forty-Year Trends in Cardiac Implantable Electronic Device Infective Endocarditis.” Open forum infectious diseases (2022). PMID: 36381626 ↗

    L2OTHERCited in: Severity Assessment and Risk Stratification, Prognosis and Natural History
  229. [229]

    Freling S, Wald-Dickler N, Banerjee J et al.. “Real-World Application of Oral Therapy for Infective Endocarditis: A Multicenter, Retrospective, Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36881940 ↗

    L2COHORTCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications, Prognosis and Natural History
  230. [230]

    Robson C, Tan B, Stuart R et al.. “A systematic review of optimal pharmacokinetic/pharmacodynamic parameters for beta-lactam therapy in infective endocarditis.” The Journal of antimicrobial chemotherapy (2023). PMID: 36691839 ↗

    L5SR_OBSCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  231. [231]

    Rallet B, Pouy R, Coutureau C et al.. “Should We Extend the Use of Oral Antibiotics in Infective Endocarditis? The ENDO-ORAL Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 40823988 ↗

    L2OTHERCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  232. [232]

    Danneels P, Hamel JF, Picard L et al.. “Impact of Enterococcus faecalis Endocarditis Treatment on Risk of Relapse.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36124844 ↗

    L2OTHERCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  233. [233]

    Goff DA, Mangino JE, Glassman AH et al.. “Review of Guidelines for Dental Antibiotic Prophylaxis for Prevention of Endocarditis and Prosthetic Joint Infections and Need for Dental Stewardship.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31728507 ↗

    L5REVIEW_NARRATIVECited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prevention, Infection Control and Special Populations
  234. [234]

    Frondizi F, Leanza GM, Chiuchiarelli M et al.. “The Use of Oritavancin as Consolidation Therapy for Infective Endocarditis Caused by Enterococcus spp.” Open forum infectious diseases (2025). PMID: 40799789 ↗

    L4TRIAL_NONRANDOMCited in: Empiric and Acute Management
  235. [235]

    Katragadda S, Baddour LM, Chesdachai S et al.. “Postoperative Treatment Regimens in Patients With Native Valve Endocarditis due to Staphylococcus aureus Who Undergo Valve Replacement or Repair.” Open forum infectious diseases (2025). PMID: 40207048 ↗

    L2TRIAL_NONRANDOMCited in: Empiric and Acute Management, Complications
  236. [236]

    Jordan H, Kozierowski K, Pickles R et al.. “Oritavancin for the Treatment of Staphylococcus aureus Bacteremia-A Retrospective Single-arm Cohort Study.” Open forum infectious diseases (2025). PMID: 40657166 ↗

    L4TRIAL_NONRANDOMCited in: Empiric and Acute Management
  237. [237]

    Duval X, Leport C. “Prophylaxis of infective endocarditis: current tendencies, continuing controversies.” The Lancet. Infectious diseases (2008). PMID: 18353264 ↗

    L5REVIEW_NARRATIVECited in: Empiric and Acute Management, Complications, Prevention, Infection Control and Special Populations
  238. [238]

    Cairns KA, Udy AA, Peel TN et al.. “Therapeutics for Vancomycin-Resistant Enterococcal Bloodstream Infections.” Clinical microbiology reviews (2023). PMID: 37067406 ↗

    L5REVIEW_NARRATIVECited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  239. [239]

    Rebechi MT, Heil EL, Luethy PM et al.. “Streptococcus pyogenes Infective Endocarditis-Association With Injection Drug Use: Case Series and Review of the Literature.” Open forum infectious diseases (2021). PMID: 34262985 ↗

    L4CASE_REPORTCited in: Empiric and Acute Management
  240. [240]

    El-Dalati S, Castillo MRC, Strnad L et al.. “Shared Decision-Making for Partial Oral Antibiotic Treatment of Infective Endocarditis: A Case Series.” Open forum infectious diseases (2024). PMID: 38585184 ↗

    L4CASE_REPORTCited in: Empiric and Acute Management
  241. [241]

    Herrera-Hidalgo L, López-Cortes LE, Luque-Márquez R et al.. “Ampicillin and Ceftriaxone Solution Stability at Different Temperatures in Outpatient Parenteral Antimicrobial Therapy.” Antimicrobial agents and chemotherapy (2020). PMID: 32393486 ↗

    L5OTHERCited in: Empiric and Acute Management
  242. [242]

    García-de-la-Mària C, Marco F, Armero Y et al.. “Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis.” Antimicrobial agents and chemotherapy (2010). PMID: 20421394 ↗

    L5OTHERCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  243. [243]

    Marco F, de la Mària CG, Armero Y et al.. “Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2008). PMID: 18426900 ↗

    L5OTHERCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  244. [244]

    Tana C, Moffa L, Tana M et al.. “Dalbavancin in the Real-World Management of Gram-Positive Infections: A Systematic Review of Randomized and Observational Studies.” Microorganisms (2026). PMID: 42197456 ↗

    L2SR_OBSCited in: Empiric and Acute Management
  245. [245]

    Ren S, Zhang L, Zhai Y et al.. “Clinical Features and Outcomes of Surgically Treated Infective Endocarditis in Adults with and Without Congenital Heart Disease: A 12-Year Cohort Study.” Journal of cardiovascular development and disease (2026). PMID: 42346445 ↗

    L2COHORTCited in: Empiric and Acute Management
  246. [246]

    Webb G, Choi J, Younes A et al.. “Comparing clinical manifestations, treatment strategies and outcomes of Staphylococcus lugdunensis bacteraemia versus Staphylococcus aureus bacteraemia - a retrospective cohort study.” Internal medicine journal (2026). PMID: 42250238 ↗

    L2COHORTCited in: Empiric and Acute Management
  247. [247]

    Festou B, Tchalla A. “Therapeutic drug monitoring in older adults treated with beta-lactams or daptomycin in a French tertiary hospital: A retrospective study (TEldBet).” Infectious diseases now (2026). PMID: 42140588 ↗

    L2COHORTCited in: Empiric and Acute Management
  248. [248]

    Combs T, Stoner BJ, McCoy P et al.. “Invasive Candida Infection in Patients With Bacterial Infective Endocarditis.” Open forum infectious diseases (2024). PMID: 38595952 ↗

    L4OTHERCited in: Empiric and Acute Management
  249. [249]

    Pericàs JM, Llopis J, Muñoz P et al.. “Outpatient Parenteral Antibiotic Treatment vs Hospitalization for Infective Endocarditis: Validation of the OPAT-GAMES Criteria.” Open forum infectious diseases (2022). PMID: 36172059 ↗

    L2OTHERCited in: Empiric and Acute Management
  250. [250]

    Rodger L, Shah M, Shojaei E et al.. “Recurrent Endocarditis in Persons Who Inject Drugs.” Open forum infectious diseases (2019). PMID: 31660358 ↗

    L2OTHERCited in: Empiric and Acute Management
  251. [251]

    Abulimiti K, Yiming N, Zou Q et al.. “Native Aortic and Mitral Valve Endocarditis Caused by Brucella: A Rare Case Report and Systematic Review.” Cardiology in review (2026). PMID: 42308361 ↗

    L4SR_OBSCited in: Empiric and Acute Management
  252. [252]

    Alhafez H, Ahmad OM, Kananyan M et al.. “Intracranial mycotic aneurysms in pediatric patients: A systematic review.” Surgical neurology international (2026). PMID: 42116912 ↗

    L4SR_OBSCited in: Empiric and Acute Management
  253. [253]

    Pericà S JM, Llopis J, González-Ramallo V et al.. “Outpatient Parenteral Antibiotic Treatment for Infective Endocarditis: A Prospective Cohort Study From the GAMES Cohort.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30649282 ↗

    L2COHORTCited in: Definitive Therapy, Duration and De-escalation
  254. [254]

    Corey GR. “Staphylococcus aureus bloodstream infections: definitions and treatment.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2009). PMID: 19374581 ↗

    L5CASE_REPORTCited in: Definitive Therapy, Duration and De-escalation
  255. [255]

    Vale C, Sime FB, Cotta MO et al.. “Therapeutic drug monitoring and the role of pharmacokinetics/pharmacodynamics in optimizing beta-lactam antibiotic dosing for deep-seated infections: a systematic review.” The Journal of antimicrobial chemotherapy (2026). PMID: 41982169 ↗

    L2SR_OBSCited in: Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  256. [256]

    Herrera-Hidalgo L, de Alarcón A, López-Cortes LE et al.. “Is Once-Daily High-Dose Ceftriaxone plus Ampicillin an Alternative for Enterococcus faecalis Infective Endocarditis in Outpatient Parenteral Antibiotic Therapy Programs?” Antimicrobial agents and chemotherapy (2020). PMID: 33046488 ↗

    L4OTHERCited in: Definitive Therapy, Duration and De-escalation, Complications
  257. [257]

    Bellouard R, Rambaud A, Delaunay C et al.. “Development and validation of a dosing nomogram for continuous infusion cloxacillin in infective endocarditis.” The Journal of antimicrobial chemotherapy (2023). PMID: 36760090 ↗

    L2OTHERCited in: Definitive Therapy, Duration and De-escalation
  258. [258]

    Cooper MM, Preslaski CR, Shihadeh KC et al.. “Multiple-Dose Dalbavancin Regimens as the Predominant Treatment of Deep-Seated or Endovascular Infections: A Scoping Review.” Open forum infectious diseases (2021). PMID: 34738025 ↗

    L5REVIEW_NARRATIVECited in: Definitive Therapy, Duration and De-escalation
  259. [259]

    Sekar P, Johnson JR, Thurn JR et al.. “Comparative Sensitivity of Transthoracic and Transesophageal Echocardiography in Diagnosis of Infective Endocarditis Among Veterans With Staphylococcus aureus Bacteremia.” Open forum infectious diseases (2017). PMID: 28470017 ↗

    L2OTHERCited in: Definitive Therapy, Duration and De-escalation
  260. [260]

    Al Janabi J, El Noaimi M, Sunnerhagen T et al.. “Infective Endocarditis Caused by Non-HACEK Gram-Negative Bacteria, a Registry-Based Comparative Study.” Open forum infectious diseases (2025). PMID: 40059980 ↗

    L3OTHERCited in: Definitive Therapy, Duration and De-escalation
  261. [261]

    Shah NH, Shutt KA, Doi Y. “Ampicillin-Ceftriaxone vs Ampicillin-Gentamicin for Definitive Therapy of Enterococcus faecalis Infective Endocarditis: A Propensity Score-Matched, Retrospective Cohort Analysis.” Open forum infectious diseases (2021). PMID: 34805443 ↗

    L2OTHERCited in: Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Complications
  262. [262]

    Assayed A, Aburumman S, Altahhan AH et al.. “Do Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio Predict In-Hospital and Long-Term Mortality in Endocarditis Patients?: A Systematic Review and Meta-Analysis.” Cardiology in review (2026). PMID: 42361207 ↗

    L2SR_OBSCited in: Definitive Therapy, Duration and De-escalation
  263. [263]

    Cairns KA, Abbott IJ, Udy AA et al.. “Vancomycin-resistant Enterococcus infective endocarditis: A case series and review of the literature.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 42235917 ↗

    L4CASE_REPORTCited in: Definitive Therapy, Duration and De-escalation
  264. [264]

    Cojutti PG, Pascale R, Grechi A et al.. “Pharmacokinetic/Pharmacodynamic Analysis of High-Dose Daptomycin in Combination with Continuous Infusion Ceftobiprole in a Case Series of Documented Staphylococcal Bacteremia or Endocarditis: Is There Any Room for TDM-Guided Dosing Reduction?” Antibiotics (Basel, Switzerland) (2026). PMID: 41892476 ↗

    L4CASE_REPORTCited in: Definitive Therapy, Duration and De-escalation
  265. [265]

    Wei CY, Lee HC, Liu LT et al.. “Case Report: Native aortic valve Listeria monocytogenes endocarditis in an adult with Evans syndrome.” Frontiers in immunology (2026). PMID: 41822507 ↗

    L4CASE_REPORTCited in: Definitive Therapy, Duration and De-escalation, Prevention, Infection Control and Special Populations
  266. [266]

    Tran LNB, Zhuo R, Singha M et al.. “First reported case of Capnocytophaga cynodegmi infective endocarditis: A diagnostic odyssey.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41619833 ↗

    L4CASE_REPORTCited in: Definitive Therapy, Duration and De-escalation
  267. [267]

    Mularoni A, Mikulska M, Barbera F et al.. “Molecular Analysis With 16S rRNA PCR/Sanger Sequencing and Molecular Antibiogram Performed on DNA Extracted From Valve Improve Diagnosis and Targeted Therapy of Infective Endocarditis: A Prospective Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 35686318 ↗

    L2COHORTCited in: Antimicrobial Resistance and Stewardship
  268. [268]

    Zhang R, Polenakovik H, Barreras Beltran IA et al.. “Emergence of Dalbavancin, Vancomycin, and Daptomycin Nonsusceptible Staphylococcus aureus in a Patient Treated With Dalbavancin: Case Report and Isolate Characterization.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 35510938 ↗

    L4CASE_REPORTCited in: Antimicrobial Resistance and Stewardship
  269. [269]

    Fujitani S, Rowlinson MC, George WL. “Penicillin G-resistant viridans group streptococcal endocarditis and interpretation of the American Heart Association's Guidelines for the Treatment of Infective Endocarditis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18444825 ↗

    L4CASE_REPORTCited in: Antimicrobial Resistance and Stewardship
  270. [270]

    Lagier JC, Aubry C, Delord M et al.. “From Expert Protocols to Standardized Management of Infectious Diseases.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2017). PMID: 28859349 ↗

    L5OTHERCited in: Antimicrobial Resistance and Stewardship, Prevention, Infection Control and Special Populations
  271. [271]

    Knoll B, Tleyjeh IM, Steckelberg JM et al.. “Infective endocarditis due to penicillin-resistant viridans group streptococci.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2007). PMID: 17516402 ↗

    L2OTHERCited in: Antimicrobial Resistance and Stewardship
  272. [272]

    Naber CK. “Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2009). PMID: 19374578 ↗

    L5OTHERCited in: Antimicrobial Resistance and Stewardship, Prevention, Infection Control and Special Populations
  273. [273]

    Durante-Mangoni E, Casillo R, Bernardo M et al.. “High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 22100575 ↗

    L4OTHERCited in: Antimicrobial Resistance and Stewardship
  274. [274]

    Colin V, Guerpillon B, Blot M et al.. “Infectious endocarditis caused by Elizabethkingia spp.: Two case reports and a literature review.” Journal of infection and public health (2025). PMID: 40915003 ↗

    L4CASE_REPORTCited in: Antimicrobial Resistance and Stewardship
  275. [275]

    El Ghali A, Stamper K, Kunz Coyne AJ et al.. “Ciprofloxacin in combination with bacteriophage cocktails against multi-drug resistant Pseudomonas aeruginosa in ex vivo simulated endocardial vegetation models.” Antimicrobial agents and chemotherapy (2023). PMID: 37877697 ↗

    L5OTHERCited in: Antimicrobial Resistance and Stewardship
  276. [276]

    Banerjee A, Kaplan JB, Soherwardy A et al.. “Characterization of TEM-1 β-Lactamase-Producing Kingella kingae Clinical Isolates.” Antimicrobial agents and chemotherapy (2013). PMID: 23796935 ↗

    L4OTHERCited in: Antimicrobial Resistance and Stewardship
  277. [277]

    Reissier S, Saleh-Mghir A, Guerin F et al.. “In vivo daptomycin efficacy against experimental vancomycin-resistant Enterococcus faecium endocarditis.” The Journal of antimicrobial chemotherapy (2018). PMID: 29329389 ↗

    L5OTHERCited in: Antimicrobial Resistance and Stewardship
  278. [278]

    Cañas MA, García-González J, Luque-Paz D et al.. “In vitro and in vivo activity of daptomycin plus ceftaroline for the treatment of experimental endocarditis due to Enterococcus faecalis with and without high-level aminoglycoside resistance.” The Journal of antimicrobial chemotherapy (2026). PMID: 42017201 ↗

    L5OTHERCited in: Antimicrobial Resistance and Stewardship
  279. [279]

    Kambarev S, Pecorari F, Corvec S. “Novel Tn916-like elements confer aminoglycoside/macrolide co-resistance in clinical isolates of Streptococcus gallolyticus ssp. gallolyticus.” The Journal of antimicrobial chemotherapy (2018). PMID: 29438479 ↗

    L4OTHERCited in: Antimicrobial Resistance and Stewardship
  280. [280]

    Awad AS, Mangold AS, Ainechi A et al.. “Causes, Predictors, and Treatment of Vasoplegia in Cardiac Surgery: A Narrative Review.” Anesthesia and analgesia (2026). PMID: 42268652 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
  281. [281]

    Ishak A, Qadeer YK, AlRawashdeh MM et al.. “Infective Endocarditis: A Contemporary Review of Epidemiology, Diagnosis, and Management.” Antibiotics (Basel, Switzerland) (2026). PMID: 42192704 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
  282. [282]

    Meena DS, Kumar D, Bohra GK. “Combination antibiotic therapy in Staphylococcus aureus endocarditis: evidence, controversies, and future directions.” Infection (2026). PMID: 42149364 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
  283. [283]

    Prezioso A, Pecora D, Dell'Aquila A et al.. “Rethinking Antibiotic Prophylaxis in Femoral-Access Catheter Ablation: A Pragmatic, Risk-Based Proposal.” Journal of clinical medicine (2026). PMID: 41827200 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship, Prevention, Infection Control and Special Populations
  284. [284]

    Ladines-Lim JB, Nemiroff A, Cressman L et al.. “Impact of Methicillin Resistance on Outcomes of Staphylococcus aureus Bacteremia at a U.S. Center, 2023-2024.” Open forum infectious diseases (2026). PMID: 42292776 ↗

    L2OTHERCited in: Antimicrobial Resistance and Stewardship
  285. [285]

    Boleij A, van Gelder MM, Swinkels DW et al.. “Clinical Importance of Streptococcus gallolyticus infection among colorectal cancer patients: systematic review and meta-analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 21960713 ↗

    L1SR_OBSCited in: Complications
  286. [286]

    Snygg-Martin U, Giang KW, Dellborg M et al.. “Cumulative Incidence of Infective Endocarditis in Patients with Congenital Heart Disease: A Nationwide, Case-Control Study Over Nine Decades.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 34036324 ↗

    L3CASE_CONTROLCited in: Complications
  287. [287]

    Beaumont AL, Mestre F, Decaux S et al.. “Long-term Oral Suppressive Antimicrobial Therapy in Infective Endocarditis (SATIE Study): An Observational Study.” Open forum infectious diseases (2024). PMID: 38737431 ↗

    L4TRIAL_NONRANDOMCited in: Complications, Prognosis and Natural History
  288. [288]

    Aldrich JB, Madsen N, Armstrong AK et al.. “Evaluation and treatment of infective endocarditis in children and adolescents with underlying CHD: a Paediatric Acute Care Cardiology Collaborative Clinical Practice Guideline.” Cardiology in the young (2025). PMID: 41466172 ↗

    L1GUIDELINECited in: Complications
  289. [289]

    Jansen JW, Linneman TW, Tan X et al.. “Comparison of Adverse Drug Reactions Between Patients Treated With Ceftaroline or Ceftriaxone: A Single-Center, Matched Cohort Study.” Open forum infectious diseases (2019). PMID: 31281870 ↗

    L2COHORTCited in: Complications
  290. [290]

    Posner C, Füssl E, Koyun F et al.. “Antithrombotic therapy in infective endocarditis: Long-term clinical outcomes of a retrospective cohort study.” Clinical research in cardiology : official journal of the German Cardiac Society (2026). PMID: 41661255 ↗

    L2COHORTCited in: Complications
  291. [291]

    Le Banner E, Le Moulec J, Kerjouan M et al.. “A contemporary picture of bacterial infections in patients with hereditary hemorrhagic telangiectasia: A nationwide cohort study.” The Journal of infection (2026). PMID: 41544822 ↗

    L2COHORTCited in: Complications, Prevention, Infection Control and Special Populations
  292. [292]

    García-de-la-Mària C, Pericas JM, Del Río A et al.. “Early in vitro and in vivo development of high-level daptomycin resistance is common in mitis group Streptococci after exposure to daptomycin.” Antimicrobial agents and chemotherapy (2013). PMID: 23478959 ↗

    L5OTHERCited in: Complications
  293. [293]

    Lodise TP, McKinnon PS, Levine DP et al.. “Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2007). PMID: 17664322 ↗

    L2OTHERCited in: Complications
  294. [294]

    Abdelhady W, Bayer AS, Seidl K et al.. “Reduced vancomycin susceptibility in an in vitro catheter-related biofilm model correlates with poor therapeutic outcomes in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2013). PMID: 23295925 ↗

    L5OTHERCited in: Complications
  295. [295]

    Bock M, Van Hasselt JGC, Schwartz F et al.. “Rifampicin reduces plasma concentration of linezolid in patients with infective endocarditis.” The Journal of antimicrobial chemotherapy (2023). PMID: 37823408 ↗

    L4OTHERCited in: Complications
  296. [296]

    Cerón I, Muñoz P, Marín M et al.. “Efficacy of daptomycin in the treatment of enterococcal endocarditis: a 5 year comparison with conventional therapy.” The Journal of antimicrobial chemotherapy (2014). PMID: 24532682 ↗

    L2OTHERCited in: Complications
  297. [297]

    Ho J, Archuleta S, Sulaiman Z et al.. “Safe and successful treatment of intravenous drug users with a peripherally inserted central catheter in an outpatient parenteral antibiotic treatment service.” The Journal of antimicrobial chemotherapy (2010). PMID: 20864497 ↗

    L2OTHERCited in: Complications
  298. [298]

    Duncan CJ, Barr DA, Ho A et al.. “Risk factors for failure of outpatient parenteral antibiotic therapy (OPAT) in infective endocarditis.” The Journal of antimicrobial chemotherapy (2013). PMID: 23475647 ↗

    L2OTHERCited in: Complications
  299. [299]

    San-Juan R, Fernández-Ruiz M, Gasch O et al.. “High vancomycin MICs predict the development of infective endocarditis in patients with catheter-related bacteraemia due to methicillin-resistant Staphylococcus aureus.” The Journal of antimicrobial chemotherapy (2017). PMID: 28379553 ↗

    L2OTHERCited in: Complications
  300. [300]

    Boccuto F, Barracano R, Guglielmi G et al.. “Transition from Paediatric to Adult Care in Congenital Heart Disease: A Call for Action.” Journal of clinical medicine (2025). PMID: 41464771 ↗

    L5REVIEW_NARRATIVECited in: Complications
  301. [301]

    Nappi F, Avtaar Singh SS. “Prevalence of healthcare-associated infections in developing and developed countries: a systematic review.” BMC infectious diseases (2026). PMID: 42046010 ↗

    L2SR_OBSCited in: Prognosis and Natural History
  302. [302]

    Østergaard L, Voldstedlund M, Bruun NE et al.. “Prevalence and Mortality of Infective Endocarditis in Community-Acquired and Healthcare-Associated Staphylococcus aureus Bacteremia: A Danish Nationwide Registry-Based Cohort Study.” Open forum infectious diseases (2022). PMID: 36540385 ↗

    L2COHORTCited in: Prognosis and Natural History
  303. [303]

    Zasowski EJ, Trinh TD, Claeys KC et al.. “Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection.” Open forum infectious diseases (2021). PMID: 35146040 ↗

    L2COHORTCited in: Prognosis and Natural History
  304. [304]

    Pavia-Velandia PX, Torres-Gómez PL, Molano-González N et al.. “Performance of predictive scores for in-hospital mortality in surgical infective endocarditis: a retrospective cohort study.” Frontiers in cardiovascular medicine (2026). PMID: 42273601 ↗

    L2COHORTCited in: Prognosis and Natural History
  305. [305]

    García-Álvarez L, Sanz MM, Marín M et al.. “Antimicrobial management of Tropheryma whipplei endocarditis: the Spanish Collaboration on Endocarditis (GAMES) experience.” The Journal of antimicrobial chemotherapy (2019). PMID: 30789210 ↗

    L4OTHERCited in: Prognosis and Natural History
  306. [306]

    Meyer-Schwickerath C, Schmidt-Hellerau K, Camp J et al.. “Health-Related Quality of Life of Patients With Infective Endocarditis-A Cross-Sectional Study Based on Data From the DERIVE Cohort.” Open forum infectious diseases (2026). PMID: 42182832 ↗

    L2OTHERCited in: Prognosis and Natural History
  307. [307]

    Duval X, Millot S, Chirouze C et al.. “Oral Streptococcal Endocarditis, Oral Hygiene Habits, and Recent Dental Procedures: A Case-Control Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2017). PMID: 28369398 ↗

    L3CASE_CONTROLCited in: Prevention, Infection Control and Special Populations
  308. [308]

    Duval X, Alla F, Hoen B et al.. “Estimated risk of endocarditis in adults with predisposing cardiac conditions undergoing dental procedures with or without antibiotic prophylaxis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2006). PMID: 16705565 ↗

    L2OTHERCited in: Prevention, Infection Control and Special Populations
  309. [309]

    Pakotiprapha A, Chungsomprasong P, Vijarnsorn C et al.. “Risk of Infective Endocarditis in Pediatric Staphylococcal Bacteremia: A 20-Year Cohort Study.” The Pediatric infectious disease journal (2026). PMID: 42115837 ↗

    L2COHORTCited in: Prevention, Infection Control and Special Populations
  310. [310]

    Athanassopoulos G, Pefanis A, Sakka V et al.. “Linezolid in prophylaxis against experimental aortic valve endocarditis due to Streptococcus oralis or Enterococcus faecalis.” Antimicrobial agents and chemotherapy (2006). PMID: 16436723 ↗

    L5OTHERCited in: Prevention, Infection Control and Special Populations
  311. [311]

    Robson C, Liu X, Al-Mukhtar O et al.. “Population pharmacokinetics and optimized prophylaxis dosing of cefazolin during transcatheter aortic valve implantation.” The Journal of antimicrobial chemotherapy (2025). PMID: 40177849 ↗

    L4OTHERCited in: Prevention, Infection Control and Special Populations
  312. [312]

    da Silva Neto MJJ, MacKay G, Agaram R et al.. “Evaluation of amoxicillin, metronidazole and gentamicin dosage regimens for use in antibiotic prophylaxis in colorectal surgery.” The Journal of antimicrobial chemotherapy (2021). PMID: 34542630 ↗

    L4OTHERCited in: Prevention, Infection Control and Special Populations
  313. [313]

    Grillo S, Isler B, Bonet-Basiero A et al.. “Does Biological Sex Determine the Natural History and Management of Infective Endocarditis?” The Canadian journal of cardiology (2025). PMID: 41197950 ↗

    L5REVIEW_NARRATIVECited in: Prevention, Infection Control and Special Populations
  314. [314]

    Iglesias-Varea J, Kirkegaard-Biosca C, Pizzi MN et al.. “Infective Endocarditis After Transcatheter Aortic Valve Implantation: Current Challenges in Diagnosis, Management, and Prevention.” The Canadian journal of cardiology (2025). PMID: 41177375 ↗

    L5REVIEW_NARRATIVECited in: Prevention, Infection Control and Special Populations
  315. [315]

    Thornhill MH, Dayer MJ, Prendergast BD et al.. “Endocarditis Prophylaxis-Indications, Application and Current Controversies.” The Canadian journal of cardiology (2025). PMID: 41101643 ↗

    L5REVIEW_NARRATIVECited in: Prevention, Infection Control and Special Populations
  316. [316]

    Hindy JR, Chesdachai S, DeSimone DC et al.. “Medical Management in Adult Patients Following Cardiac Valve Surgery for Infective Endocarditis: A Comprehensive Review.” The Canadian journal of cardiology (2025). PMID: 40953817 ↗

    L5REVIEW_NARRATIVECited in: Prevention, Infection Control and Special Populations
  317. [317]

    Latkowska-Wiśniewska M, Jakubowska S, Górski B. “Antibiotics in Mucogingival Surgery for Recession Treatment: A Narrative Review.” Antibiotics (Basel, Switzerland) (2025). PMID: 40867964 ↗

    L5REVIEW_NARRATIVECited in: Prevention, Infection Control and Special Populations
  318. [318]

    Morelli MK, Veve MP, Shorman MA. “Maternal Bacteremia Caused by Staphylococcus Aureus With a Focus on Infective Endocarditis.” Open forum infectious diseases (2020). PMID: 32766382 ↗

    L4OTHERCited in: Prevention, Infection Control and Special Populations
  319. [319]

    Vyas DA, Marinacci L, Bearnot B et al.. “Creation of a Multidisciplinary Drug Use Endocarditis Treatment (DUET) Team: Initial Patient Characteristics, Outcomes, and Future Directions.” Open forum infectious diseases (2022). PMID: 35252467 ↗

    L4OTHERCited in: Prevention, Infection Control and Special Populations
  320. [320]

    Suda KJ, Henschel H, Patel U et al.. “Use of Antibiotic Prophylaxis for Tooth Extractions, Dental Implants, and Periodontal Surgical Procedures.” Open forum infectious diseases (2017). PMID: 29326959 ↗

    L2OTHERCited in: Prevention, Infection Control and Special Populations
  321. [321]

    Weese JS, Soltero-Rivera M, Weese HE et al.. “Infectious complications of dental procedures in dogs and cats, and the impact of antimicrobial prophylaxis: a systematic review.” The Journal of small animal practice (2026). PMID: 42244488 ↗

    L5SR_OBSCited in: Prevention, Infection Control and Special Populations
  322. [322]

    Loper C, Baskette J, Fagan TR et al.. “Prophylactic Antibiotics for Prevention of Infective Endocarditis or Bacteremia in Pediatric Patients With Congenital Heart Disease Undergoing Dental Procedures: Systematic Review.” Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry (2025). PMID: 41269014 ↗

    L2SR_OBSCited in: Prevention, Infection Control and Special Populations
  323. [323]

    Zelfani S, Ernandes H, Kaoual S et al.. “Case Report: Austrian syndrome with multifocal septic arthritis in the immunocompetent elderly: expanding the clinical spectrum.” Frontiers in medicine (2026). PMID: 41675630 ↗

    L4CASE_REPORTCited in: Prevention, Infection Control and Special Populations

Revision History

All updates applied to this page

Loading revisions…